WO2003061557A2 - Levothyroxine pharmaceutical compositions, methods of making and methods of administration - Google Patents

Abstract

The present invention generally relates to stable pharmaceutical compositions, and methods of making and administering such compositions. In one aspect, the invention features stabilized pharmaceutical compositions that include pharmaceutically active ingredients such as levothyroxine (T4) sodium and liothyronine (T3) sodium (thyroid hormone drugs), preferably in an immediate release solid dosage form. Also provided are methods for making and using such immediate release and stabilized compositions.

Description

LEVOTHYROXINE PHARMACEUTICAL COMPOSITIONS, METHODS OF MAKING AND METHODS OF ADMINISTRATION

U.S. Patent Application

This application for U.S. patent is filed as a utility application under U.S.C., Title 35, §1 1 1(a).

Related U.S. Patent Applications

This application for U.S. patent claims priority to the following U.S. provisional applications, each of which was filed on August 15, 2001 , assigned Serial No. 60/312,483 and is entitled Pharmaceutical Compositions, Methods of Making and Administering Them.

Field of the Invention

The invention generally relates to stable pharmaceutical compositions, and methods of making and administering such compositions. In one aspect, the invention features stabilized pharmaceutical compositions that include pharmaceutically active ingredients such as levothyroxine (T4) sodium and liothyronine (T3) sodium (thyroid hormone drugs), preferably in an immediate release solid dosage form. Also provided are methods for making and using such immediate release and stabilized compositions.

Background

Thyroid hormone preparations of levothyroxine sodium and liothyronine sodium are phamiaceutical preparations useful to the treatment of hypothyroidisni and thyroid hormone replacement therapy in mammals, for example, humans and dogs.

Thyroid hormone preparations are used to treat reduced or absent thyroid function of any etiology, including human or animal ailments such as myxedema, cretinism and obesity.

Hypothyroidisni is a common condition. It has been reported in the United States Federal Register that Hypothyroidisni has a prevalence of 0.5 percent to 1.3 percent in adults, ln people over 60, the prevalence of primary hypothyroidisni increases to 2.7 percent in men and 7.1 percent in women. Because congenital hypothyroidisni may result in irreversible mental retardation, which can be avoided with early diagnosis and treatment, newborn screening for this disorder is mandatory in North America. Europe, and Japan.

Thyroid hormone replacement therapy can be a chronic, lifetime endeavor. The dosage is established for each patient Individually. Generally, the initial dose is small. The amount is increased gradually until clinical evaluation and laboratory tests indicate that an optimal response has been achieved. The dose required to maintain this response is then continued. The age and general physical condition of the patient and the severity and duration of hypothyroid symptoms detennine the initial dosage and the rate at which the dosage may be increased to the eventual maintenance level. It has been reported that the dosage increase should be very gradual in patients with myxedema or cardiovascular disease to prevent precipitation of angina, myocardial infarction, or stroke.

It is important that thyroid hormone treatment have the correct dosage. Both under- treatment and over-treatment can have deleterious health impacts. In the case of under-treatment, a sub-optimal response and hypothyroidisni could result. Under-treatment has also been reported to be a potential factor in decreased cardiac contractility and increased risk of coronary artery disease. Conversely, over-treatment may result in toxic manifestations of hyperthyroidism such as cardiac pain, palpitations, or cardiac arrhythmia's. In patients with coronary heart disease, even a small increase in the dose of levothyroxine sodium may be hazardous in a particular. Hyperthyroidism is a known risk factor for osteoporosis. Several studies suggest that sub clinical hyperthyroidism in premenopausal women receiving thyroid hoπnone drugs for replacement or suppressive therapy is associated with bone loss. To minimize the risk of osteoporosis, it is preferable that the dose be kept to the lowest effective dose.

Because of the risks associated with over-treatment or under-treatment with levothyroxine sodium, there is a need for thyroid hoπnone products that are consistent in potency and bioavailability. Such consistency is best accomplished by manufacturing techniques that maintain consistent amounts ofthe active moiety during tablet manufacture.

Thyroid hoπnone drugs are natural or synthetic preparations containing tetraiodothyronine (T ₄, levothyroxine) or triiodothyronine (T ₃, liothyronine) or both, usually as their phannaceutically acceptable (e.g. sodium) salts. T ₄ and T ₃ are produced in the human thyroid gland by the iodination and coupling of the amino acid tyrosine. T ₄ contains four iodine atoms and is formed by the coupling of two molecules of diiodotyrosine (DIT). T ₃ contains three atoms of iodine and is fomied by the coupling of one molecule of DIT with one molecule of monoiodotyrosine (MIT). Both hoπnones are stored in the thyroid colloid as thyroglobulin. Thyroid hormone preparations belong to two categories: (1) natural hoπnonal preparations derived from animal thyroid, and (2) synthetic preparations. Natural preparations include desiccated thyroid and thyroglobulin.

Desiccated thyroid is derived from domesticated animals that are used for food by man (either beef or hog thyroid), and thyroglobulin is derived from thyroid glands of the hog. The United States Pharmacopoeia (USP) has standardized the total iodine content of natural preparations. Thyroid USP contains not less than (NLT) 0.17 percent and not more than (NMT) 0.23 percent iodine, and thyroglobulin contains not less than (NLT) 0.7 percent of organically bound iodine. Iodine content is only an indirect indicator of true hormonal biologic activity.

Synthetic forms for both T and T ₃ thyroid hormone are available from a number of producers. For example, liothyronine sodium (T ₃) tablets are available under the trademark Cytomel^® from King Phaπnaceuticals, Inc., St. Louis, Missouri. Levothyroxine sodium (T ₄) is available under the tradename Levoxyl^® from King Phaπnaceuticals, Inc., under the tradename Synthroid^® from Knoll Pharmaceutical, Mt. Olive, New Jersey, and under the tradename Unithroid^® from Jerome Stevens Phannaceuticals, Bohemia, New York. In addition a veterinarian preparation ϋf levothyroxine sodium is available under fhe tradename Soloxine^® from King Pharmaceuticals, Inc.

Levoxyl^® (levothyroxine sodium tablets,USP) contain synthetic crystalline L-3,3',5,5 '- tetraiodothyronine sodium salt [levothyroxine (T₄) sodium]. As indicated above, the synthetic T₄ in Levoxyl^® is identical to that produced in the human thyroid gland. The levothyroxine (T₄) sodium in Levoxyl^® has an empirical formula of Cι₅Hι₀ I₄ N NaO₄ • H O, molecular weight of 798.86 g/mol (anhydrous), and a structural formula as shown:

COONa ^* /.HaO

It is well known that the stability of thyroid hormone drugs is quite poor. They are hygroscopic and degrade in the presence of moisture or light, and under conditions of high temperature. The instability is especially notable in the presence of phamiaceutical excipients. such as carbohydrates, including lactose, sucrose, dextrose and starch, as well as certain dyes. The critical nature of the dosage requirements, and the lack of stability of the active ingredients in the popular phamiaceutical formulations, have led to a crisis which has adversely effected the most prescribed thyroid drug products. See, e.g., 62 Fed. Reg. 43535 (Aug. 14, 1997).

It is desirable, therefore, to prepare a stabilized dosage of levothyroxine and liothyronine, which will have a longer shelf life that can be used in the treatment of human or animal thyroid hormone deficiency. U.S. Patent No. 5,22 5,204 (the '204 patent) is directed to improving the stability of levothyroxine sodium. In one embodiment disclosed by '204, stabilized levothyroxine sodium was prepared in a dry state by mixing levothyroxine sodium with a cellulose tableting agent using geometric dilution and subsequently combining this mixture with the same or a second cellulose tableting agent, such as microcrystalline cellulose. Other tableting aids or excipients can be used in this foπnulation. This '204 patent is incorporated by reference herein, in its entirety.

The microcrystalline cellulose disclosed In '204 is AVICEL 101^®, AV1CEL 102^®, AVICEL 103^®, AVICEL 105^®, trademarks of FMC Company of Newark, DE., and Microcrystalline Cellulose NF, or EMCOCEL^®, a trademark owned ^"by Penwest Phaπnaceuticals of Patterson, NY. These microcrystalline cellulose products are prepared by re-slurrylng the cellulose and spray drying the product. This produces an - helix spherical microcrystalline cellulose product.

U. S. Patents 5,955,105 and 6,056,975 (the continuation of '105) disclose pharmaceutical preparations of levothyroxine and microcrystalline cellulose, along with other excipients. The microcrystalline cellulose products used in the '105 and '975 patents were also the α - form Avicel microcrystalline cellulose products. U. S. Patents 5,955,105 and 6,056,975 are incorporated by reference herein, in their entirety.

Another microcrystalline cellulose product is a β - sheet form microcrystalline cellulose having a flat needle shape, marketed under the trademark CEOLUS KG801^® by FMC Company of Newark, Delaware. The Ceolus^® product has different morphology, and different performance characteristics, than those of the Avicel product. The β - sheet microcrystalline cellulose of the present invention is disclosed in U.S. Patent 5,574,150, which is hereby incorporated by reference. Further disclosure relating to β - sheet microcrystalline cellulose is found in International Journal of Pharmaceutics 182 (199) 155 which is hereby incorporated by reference.

The Ceolus product (β - sheet microcrystalline cellulose) is disclosed by FMC, in its product bulletin dated October 1997, as being suitable for "smaller size tablets" and "exceptional dmg carrying capacity." The Ceolus product was said to provide superior compressibility and drug loading capacity, that still exhibited effective flowability. The examples given in the Ceolus^® bulletin were of vitamin C combined with Ceolus^® microcrystalline cellulose at levels of from 30 to 45 weight % Ceolus^® product in the fonn of a tablet.

However, there have been problems using the Ceolus^® product. For example, at higher levels of Ceolus^® product concentration, flow problems were encountered in the process of compressing tablets, and the Ceolus^® product was considered unsuitable for compression at higher concentrations than about 45 weight %.

The is a definite need for solid levothyroxine (T4) and/or liothyronine (T3) (thyroid hormone drugs) pharmaceutical compositions, preferably in an immediate release solid dosage form, with the T4 and T3 in the form of their sodium salts that are relatively stable. There is also a- need for methods for making such immediate release and stabilized solid levothyroxine (T4) and/or liothyronine (T3) (thyroid hormone drugs) phaπnaceutical compositions.

Summary of the Invention

The present invention overcomes and alleviates the above-mentioned drawbacks and disadvantages in the thyroid drug art through the discovery of novel oral levothyroxine (T4) and/or liothyronine (T3) (thyroid hormone drugs) phamiaceutical compositions and methods.

Generally speaking, the present invention relates to stabilized solid as levothyroxine (T4) sodium and/or liothyronine (T3) sodium (thyroid hormone drugs) phannaceutical compositions and in particular, immediate release, stabilized phamiaceutical compositions that include pharmaceutically active ingredients such as levothyroxine (T4) sodium and/or liothyronine (T3) sodium (thyroid hormone drugs). Preferably but not necessarily, the novel pharmaceutical compositions are provided in a solid dosage form, such as a tablet.

The phannaceutical compositions of the present invention are useful for, among other things, as replacement or supplemental therapy in hypothyroidisni of any etiology, except transient hypothyroidisni during the recovery phase of subacute thyroiditis, suppression of pituitary TSH secretion in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, Hashimoto's thyroiditis, multinodular goiter and, as adjunctive therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer in warmblooded animals, especially humans including pediatrics.

The present invention also provides methods for making such immediate release and stabilized levothyroxine (T4) sodium and/or liothyronine (T3) sodium (thyroid hormone drugs) phaπnaceutical compositions.

Also in accordance with the present invention, because of the extraordinary release characteristics of the preferred compositions, a method of administration to children and patients who have difficulty taking pills, wherein the solid composition having the appropriate dosage is simply put in an aqueous fluid, e.g., juice, where it dissolves in a matter of 1-3 minutes, and the patient can then ingest the fluid, and receive the appropriate dosage, is now made practical.

The present invention has a wide range of important uses including providing pharmaceutically active levothyroxine compositions with enhanced bioavailability, improved shelf life, and more reliable potency. We have discovered immediate release pharmaceutical compositions that include as pharmaceutically active ingredients at least one of levothyroxine and liothyronine, preferably at least one levothyroxine salt, as the major active ingredient. Such preferred immediate release compositions desirably provide at least about 85% (w/v) dissolution of the levothyroxine salt in less than about 20 minutes as detennined by standard assays disclosed herein. Surprisingly, it has been found that by combining the phannaceutically active ingredients with specific additives in accordance with the invention, it is possible to formulate the compositions so that the ingredients are released almost immediately after ingestion or contact with an aqueous solution, e.g., in a matter of minutes. Preferred invention compositions are stable and provide better shelf life and potency characteristics than prior phamiaceutical compositions.

The immediate release pharmaceutical compositions of the invention provide important uses and advantages. A major advantage is the stability of the active ingredients in the composition. For example, while, as indicated above, prior formulations with sugars, starches, and various types of celluloses, including micro-cellular celluloses such as the Avicel products, have experienced substantial degradation of the active ingredients, e.g. T4 sodium. To deal with this problem, pharmaceutical manufacturers have over-fonnulated the T4-containing pharmaceutical compositions containing such active ingredients, so that the patient can obtain at least the prescribed dosage despite the carbohydrate-induced instability of the active ingredient. However, the patient who obtains the phaπnaceutical immediately after it is made, receives an over-dosage of the active compound; whereas, the patient who has received the pharmaceutical after it has sat on the pharmacy shelf for an extended period, will receive an under-dosage of the active ingredient. In either case, the patient receives the wrong dosage, with possible serious consequences.

In sharp contrast, it has been surprisingly found that the use of the β-sheet microcrystalline cellulose in the compositions of the present invention substantially increase the stability of the thyroid hormone drugs, so that the patient obtains consistent potency over an extended shelf life, compared to prior thyroid hormone drug products. In this application, the te i "stabilized", as applied to levothyroxine and/or liothyronine means that the loss of potency over the shelf life ofthe product is less than about 0.7 % potency per month, for at least about 18 months. Preferred compositions have a loss of potency of less than about 0.5% per month for sπch a period, and more preferred compositions have a loss of potency of less than about 0.3% per month for such a period.

Further, the compositions of the invention provide favorable pharmacokinetic characteristics when compared to prior foπnulations. In particular, the immediate release pharmaceutical compositions that include levothyroxine salt have are more quickly available for absorption by the gastrointestinal (GI) tract faster and are absorbed more completely than has heretofore been possible. This invention feature substantially enhances levothyroxine bioavailability, thereby improving efficacy and reliability of many standard thyroid hoπnone replacement strategies.

Additionally, the desirable immediate release characteristics of the present invention facilitate dosing of patients who may be generally adverse to thyroid hoπnone replacement strategies involving solid dosing. More specifically, immediate release phannaceutical compositions disclosed herein can be rapidly dissolved in an appropriate aqueous solution (e.g., water, saline, juice) or colloidal suspension (e.g., baby formula or milk) for convenient administration to such patients. Illustrative of such patients include infants, children, and adults who may experience swallowing difficulties. The invention thus makes standard thyroid hormone replacement strategies more flexible and reliable for such patients.

Accordingly, and in one embodiment, the invention features an immediate release phannaceutical composition comprising at least one levothyroxine salt, preferably one of such a salt. At least about 80% of the levothyroxine dissolves in aqueous solution in less than about 20 minutes as determined by a standard assay, disclosed herein. Preferably, at least about 80% of the levothyroxine is dissolved in the aqueous solution by about 15 minutes from the time that the composition, in pill form, is placed in the aqueous solution. More preferably, at least about 85% of the levothyroxine is released to the aqueous solution by about 10 minutes, most preferably by about 5 minutes after exposure of the composition to the aqueous solution. As shown below, compositions in accordance with the present invention can be fo iulated to release 85% of the levothyroxine within 2-3 minutes after exposure to the aqueous solution.

It has been found that by combining one or more of the pharmaceutically active agents with β-foπn microcrystalline cellulose, it is possible to produce compositions with favorable immediate release characteristics. Without wishing to be bound to theoiy, it is believed that the agents do not bind well to certain grades of the β - sheet form microcrystalline cellulose. More 3f the agent is thus available for immediate release. In contrast, it is believed that many prior formulations have active agents that bind cellulose additives, making less available. The release characteristics of the compositions of the invention are also improved by the use of other agents, as discussed further below.

Thus in one embodiment, the present invention relates to a stabilized phaπnaceutical composition comprising a pharmaceutically active ingredient, such as levothyroxine, and the β - sheet form of microcrystalline cellulose, in the fonn of a solid dosage. More specifically, the present invention relates to a stabilized pharmaceutical composition comprising a pharmaceutically active ingredient, such as levothyroxine sodium and/or liothyronine sodium, at least about 50 weight % ofthe dosage weight composed of the β - sheet form of microcrystalline cellulose, and, optionally, additional excipients, in a solid dosage form.

In another aspect, the invention provides an aqueous solution or colloidal suspension that includes at least one of the compositions of this invention, preferably between from about one to about five of same, more preferably about one of such compositions.

It has also been found that β - sheet microcrystalline cellulose grades having preferred bulk densities provide for more compact processing than use of other celluloses. That is, use of the β - sheet microcrystalline cellulose having bulk densities in accord with this invention helps to provide for higher compression ratios (initial volume/final volume). As discussed below, other invention aspects help reduce or avoid production of damaging compression heat that has damaged prior formulations made from high compression ratios. The compositions of the present invention generally also require less compressional force to form the tablets.

Accordingly, the invention also provides methods for making an immediate release pharmaceutical composition comprising at least one levothyroxine salt, preferably one of such a salt. In one embodiment, the method includes at least one and preferably all of the following steps: a) mixing a levothyroxine salt with microcrystalline β-cellulose and preferably a crosscarmellose salt to make a blend; and

b) compressing the blend in a ratio of initial volume to final volume of between from about 2:1 to about 5:1 to make the composition, preferably about 4:1. In one embodiment, the method involves preparing an oral dosage form of a phannaceutically active ingredient comprising dry blending the pharmaceutically active ingredient and at least about 50 weight % of the β - sheet fomi of microcrystalline cellulose, and compressing the blend to form a solid dosage.

These and other objects, features, and advantages of the present invention may be better understood and appreciated from the following detailed description of the embodiments thereof, selected for purposes of illustration and shown in the accompanying figures and examples. It should therefore be understood that the particular embodiments illustrating the present invention are exemplary only and not to be regarded as limitations ofthe present invention.

Brief Description of the Figs.

The foregoing and other objects, advantages and features of the invention, and the manner in which the same are accomplished, will become more readily apparent upon consideration of the following detailed description ofthe invention taken in conjunction with the accompanying Figs., which illustrate a preferred and exemplary embodiment, wherein:

Figures IA - IC illustrate various solid dosage fonns such as cylindrical tablets and raised violin shaped tablets;

Figure 2 illustrates a tableting die pair;

Figure 3 pair; is graphical depiction of comparative dissolution data of various strengths of Levoxyl^® tablets made in accordance with the invention.

Figure 4A is an HPLC chromatogram showing a levothryoxine and liothyronine standards.

Figure 4B is an HPLC chromatograph showing results of levothyroxine sodium sample made in accordance with the present invention.

Figure 5A is a chromatogram showing various levothryoxine impurity standards.

Figure 5B is a chromatograph showing results of levothyroxine sodium sample made in accordance with the present invention. Detailed Description

By way of illustrating and providing a more complete appreciation of the present invention and many of the attendant advantages thereof, the following detailed description is given concerning the novel oral levothyroxine (T4) and/or liothyronine (T3) (thyroid hormone drugs) pharmaceutical compositions and methods for use in warm-blooded animals, especially humans and children.

As discussed, the invention relates to immediate release solid phamiaceutical compositions such as stabilized pharmaceutical compositions that include pharmaceutically active ingredients such as levothyroxine (T4) sodium and liothyronine (T3) sodium (thyroid hormone drugs), preferably in a solid dosage form. Also provided are methods for making such immediate release and stabilized compositions.

Aspects ofthe present invention have been disclosed in U.S. Provisional Application No. 60/269,089, entitled Stabilized Pharmaceutical and Thyroid Hormone Compositions and Method of Preparation and filed on February 15, 2001 by Franz, G.A. et al. The disclosure of said provisional application is incorporated herein by reference.

By the phrase "immediate release" is meant a pharmaceutical composition in which one or more active agents therein demonstrates at least about 80% (w/v) dissolution, preferably between from about 90% (w/v) to about 95% (w/v), more preferably about 95% (w/v) to about 99% (w/v) or more within 15 to 20 minutes as determined by a standard dissolution test. Suitable standard dissolution tests are known in the field. See FDA, Center for Drug Research, Guidance for Industry, In Vivo Pharmacokinetics and Bioavailability Studies and In Vitro Dissolution Testing for Levothyroxine Sodium Tablets, available at www.fda.gov/cder/guidance/index.htm. A specifically preferred dissolution test is provided in Example 2, below.

A pharmaceutical composition of the invention is "stable" or "stabilized" if one or more ofthe active agents therein exhibit good stability as deteπnined by a standard potency test. More specifically, such compositions exhibit a potency loss of less than about 15%, preferably less than about 10%, more preferably less than about 1% to about 5% as determined by the test. Potency can be evaluated by one or a combination of strategies known in the field. See the USP. A preferred potency test compares loss or conversion of the active agent in the presence (experimental) or absence (control) of a carrier or excipient. A specifically preferred potency test is provided in Examples 1 and 3, below.

In preferred embodiments, the phannaceutical compositions of the invention include, as active agent, levothyroxine (T4), preferably a salt thereof such as levothyroxine sodium USP. Such compositions typically exhibit a levothyroxine (T4) plasma Cήiax of between from about 12 μg/dl to about 16 μg/dl, preferably as determined by the standard Cmax test. Preferably, the In(Cmax) ofthe levothyroxine (T4) plasma level is between from about 1 to about 3.

The standard Cmax test can be performed by one or a combination of strategies known in the field. See e.g., the USP. A preferred Cmax test is disclosed below in Examples 8 and 9.

Additionally preferred compositions in accord with the invention provide a triiodothyronine (T3) plasma Cmax of between from about 0.1 ng/ml to about lOng/ml, preferably 0.5 ng/ml to about 2ng/ml, as determined by the standard Cmax test. Typically, the In(Cmax) is between from about 0.01 to about 5. See Examples 8 and 9 for more infonnation.

Further preferred compositions exhibit a levothyroxine (T4) plasma Tmax of between from about 0.5 hours to about 5 hours, preferably as determined by a standard Tmax test. The standard Tmax test can be perfoπned by procedures generally known in the field. See e.g., the USP. A preferred Tmax test is disclosed below in Examples 8 and 9.

Still further preferred compositions of the invention exhibit a triiodothyronine (T3) plasma Tmax of between from about 10 hours to about 20 hours, preferably about 12 to about 16 hours as determined by the standard Tmax test.

Additionally preferred invention compositions feature a levothyroxine (T4) plasma AUC (0-t) of between from about 450 μg-hour/dl to about 600 μg-hour/dl, preferably 500 μg-hour/dl to about 550 μg-hour/dl as determined by a standard AUC (0-t) test. Preferably, the ln[AUC(0- t)] is between from about 1 to about 10.

Standard methods for performing AUC (0-t) lest determinations are generally known in the field. See e.g., the USP. Examples 8 and 9 below provide a specifically preferred method of detem ining the AUC (0-t).

Further preferred invention compositions feature a triiodothyronine (T3) AUC (0-t) of between from about 10 ng-hour/ml to about 100 ng-hour/ml, preferably 20 ng-hour/ml to about 60 ng-hour/ml, as deteπnined by the standard AUC (0-t) test. Preferably, the In[AUC(0-t)] is between from about 1 to about 5.

As will be appreciated, many prior pharmaceutical fonnulations include lactose or other sugars as a phannaceutically acceptable carrier. It has been found however, that sugars such as lactose can react with active agents including the levothyroxine (T4) compositions of the present invention. For example, and without wishing to be bound to theory, it is believed that lactose is particularly damaging to T4 and T3 molecules via Schiff reactions. The invention address this problem by providing compositions that are essentially sugar-free. Particular invention compositions are essentially free of lactose.

Additionally, preferred phannaceutical compositions of the invention are provided in which the active material is a non-granulated material. Prior levothyroxine compositions have been granulated in various size reduction machines to grains of less than, e.g., 5 - 20 microns average particle size in order to be effectively incorporated into the administrate pharmaceutical composition. The granulation process subjects the active material to degrading heat, which can have adverse effects on the active material, as well as reducing the activity level. Prior manufacturers purchase micronized levothyroxine manufactured under DMF No. 4789, and then granulate it before incorporating it into the levothyroxine phamiaceutical product.

In the preferred method ofthe present invention, the raw material is not granulated before incorporation into the pharmaceutical composition. Rather, the ingredients of the preferred phamiaceutical are mixed and the mixture is subjected to direct compression to fonn the pharmaceutical tablets of appropriate dosage. As a result, the activity of the active ingredient is not degraded prior to the direct compression step. Bulk levothyroxine is obtained in a fine powdered form, preferably from Biochemie GmbH, A-6250 Kundl, Austria. More importantly, the use of the preferred process results in a product which is immediately dispersible in aqueous solution, to make the active ingredient available for absorption in the body. As used in this application, "non-granulated" means that the bulk USP compound is used without subjecting it to granulators or similar high energy size reduction equipment before being mixed with the other phaπnaceutical components and fonned into the appropriate pill. Preferably, the bulk active ingredient is mixed with the appropriate amounts of other ingredients and directly compressed into pill form. Since it is not necessary to granulate the material, it is not necessary to subject it to degrading temperatures in the process of foπning the phaπnaceutical compositions containing the active materials. In the present process we start with micronized active material, which merely needs to be blended with the B and other materials and then compressed. Others have to be granulated, and then dried, which steps interfere with the dissolution of the active material. The drying temperatures employed in manufacturing other active ingredients can cause degradation of the levothyroxine, as experienced in other available thyroxine. It has been found that providing the invention compositions in a non-granulated format helps to reduce or eliminate ^"active ^"agent ^"degradation, presumably by facilitating a reduction in friction, and thus degrading heat, during compression ofthe compositions into pills.

Practice of the invention is compatible with several β-form microcrystalline cellulose grades. Preferably, the β-form microcrystalline cellulose has a bulk density of between from about 0.10 g/cm³ to about 0.35 g/cm³, more preferably between from about 0.15 g/cm³ to about 0.25 g/cm³, still more preferably between from about 0.17 g/cm³ to about 0.23 g/cm³, most preferably between from about 0.19 g/cm to about 0.21 g/cm .

Further preferred grades of the β-fonn microcrystalline cellulose are substantially non- conductive. Preferably, the β-form microcrystalline cellulose has a conductivity of less than about 200 μS/cm, more preferably, less than about 75 μS/cm, still more preferably between from about 0.5 μS/cm to 50 μS/cm, most preferably between from about 15 μS/cm to 30 μS/cm.

A specifically preferred β-fonn microcrystalline cellulose is sold by Asahi Chemical Industry Co., Ltd (Tokyo, Japan) as Ceolus (Type KG-801 and/or KG-802).

Additionally preferred compositions of the invention have a post-packaging potency of between from about 95% to about 120%, preferably 98% to about 110% as deteπnined by the standard potency test.

The present invention is a phaπnaceutical product that is in the fom of a solid dosage, such as a sublingual lozenge, buccal tablet, oral lozenge, suppository or a compressed tablet. The phaπnaceutically active ingredient is dry mixed with the β-form of the microcrystalline cellulose, optionally with additional excipients, and fomied into a suitable solid dosage.

Preferred tablets according to the invention have a total hardness of between from about 1 to about 30 KP, preferably about 6 to about 14 KP as deteπnined by a standard hardness test. Methods for determining tablet hardness are generally known in the field. See e.g., the USP. A preferred standard hardness test is disclosed below in Example 4.

Additionally preferred phannaceutical compositions including those in tablet fonnat preferably include less than about 10% total impurities, more preferably less than about 5% of same as determined by a standard impurity test.

Reference herein to the "standard impurity test" means a USP recognized assay for detecting and preferably quantitating active drug degradation products. In embodiments in which levothyroxine or liothyronine break-downs are to be monitored, such products include, but are not limited to, at least one of diiodothyronine (T2), triiodothyronine (T3), levothyroxine, trtiϋdo hyrδacetic acid amide, triiό lόihy oemylarriirie, tπiδdolhyroacetic acid, triiodothyroethyl alcohol, tetraiodothyroacetic acid amide, tetraiodothyroacetic acid, triiodothyroethane, and tetraiodothyroethane. Of particular interest are diiodothyronine (T2), triiodothyronine (T3), triiodothyroacetic acid, and tetraiodothyroacetic acid impurities.

A preferred impurity test for monitoring levothyroxine and liothyronine breakdown products involves liquid chromatography (LC) separation and detection, more preferably HPLC. Specifically preferred impurity tests are provided below in Examples 5 and 6

Further preferred compositions in accord with the invention include one or more standard disintegrating agents, preferably crosscamiellose, more preferably a salt of same. Still further preferred compositions include a phamiaceutically acceptable additive or excipient such as a magnesium salt.

The present invention can be prepared as a direct compression formula, dry granulation formula, or as a wet granulation foπnula, with or without preblending of the drug, although preferably with preblending.

The pharmaceutically active ingredient can be any type of medication which acts locally in the mouth or systemically, which is the case of the latter, can be administered orally to transmit the active medicament into the gastrointestinal tract and into the blood, fluids and tissues of the body. Alternatively, the medicament can be of any type of medication which acts through the buccal tissues of the mouth to transmit the active ingredient directly into the blood stream thus avoiding first liver metabolism and by the gastric and intestinal fluids which often have an adverse inactivating or destructive action on many active ingredients unless they are specially protected against such fluids as by means of an enteric coating or the like. The active ingredient can also be of a type of medication which can be transmitted into the blood circulation through the rectal tissues.

Representative active medicaments include antacids, antimicrobials, coronary dilators, peripheral vasodilators, anti psychotropics, antimanics, stimulants, antihistamines, laxatives, decongestants, vitamins, gastrosedatives, antidiarrheal preparations, vasodilators, antiarrythmics, vasoconstrictors and migraine treatments, anticoagulants and antithrombotic drugs, analgesics, antihypnotics, sedatives, anticonvulsants, neuromuscular drugs, hyper and hypoglycemic agents, thyroid and antithyroid preparations, diuretics, antispasmodics, uterine relaxants, mineral and nutritional additives, antiobesity drugs, anabolic drugs, erythropoietic drugs, antiasthematics, expector nts, couglf su ψressants,Tnucolytics, ahtiuf icerhic drags, and drags or substances acting locally in the mouth.

Typical active medicaments include gastrointestinal sedatives such as metoclopramide and propantheline bromide, antacids such as aluminum trisilicate, aluminum hydroxide and cimetidine, asprin-like drags such as phenylbutazone, indomethacin, and naproxen. ibuprofen, flurbiprofen, diclofenac, dexamethasone, prednisone and prednisolone, coronary vasodialator drags such as glyceryl trinitrate, isosorbide dinitrate and pentaerythritol tetranitrate, peripheral and cerebral vasodilators such as soloctidilum, vincamine, naftidrofuryl oxalate, comesylate, cyclandelate, papaverine and nicotinic acid, antimicrobials, such as erythromycin stearate, cephalexin, nalidixic acid, tetracycline hydrochloride, ampicillin, flucolaxacillin sodium, hexamine mandelate and hexamine hippurate, neuroleptic drags such as fluazepam, diazepam, temazepam, amitryptyline, doxepin, lithium carbonate, lithium sulfate, chlorpromazine, thioridazine, trifluperazine, fluphenazine, piperothiazine, haloperidol, maprotiline hydrochloride, imipramine and desmethylimipramine, central nervous stimulants such as methylphenidate, ephedrine, epinephrine, isoproterenol, amphetamine sulfate and amphetamine hydrochloride, anitidrugs such as diphenylhydramine, diphenylpyramine, chlorpheniramine and brompheniramine, antidiarrheal drugs such as bisacodyl and magnesium hydroxide, the laxative drag, dioctyl sodium sulfosuccinate, nutritional supplements such as ascorbic acid, alpha tocopherol, thiamine and pyridoxine, antispasmotics such as dicyclomine and diphenoxylate, drags effecting the rhythm of the heart such as verapamil, nifedepine. diltiazem, procainamide, disopyramide, bretylium tosylate, quinidine sulfate and quinidine gluconate, drugs used in the treatment of hypertension such as propranolol hydrochloride, guanethidine monosulphate, methyldopa, oxprenolol hydrochloride, captopril, Actace and hydralazine, drags used in the treatment of migraine such as ergotamine, drugs effecting coagulability of blood such as epsilon aminocaproic acid and protamine sulfate, analgesic drugs such as acetylsalicyclic acid, acetaminophen, codeine phosphate, codeine sulfate, oxycodone, dihydrocodeine tartrate, oxydodeinone, morphine, heroin, nalbuphine, butorphanol tartrate, pentazocine hydrochloride, cyclazacine, pethidine, buprenorphine, scopolamine and mefenamic acid, antidrugs such as phenytoin sodium and sodium valproate, neuromuscular drugs such as dantrolene sodium, substances used in the treatment of diabetes, such as tolbutamide, diabenase glucagon and insulin, drugs used in the treatment of thyroid gland dysfunction such as triiodothyronine, liothyronine sodium, levδthyfόxilne sodium and related compounds, and propylthiouracil, diuretic drags, such as furosemide, chlorthalidone, hydrochlorthiazide, spironolactone and triampterene, the uterine relaxant drugritodrine, appetite suppressants such as fenfluramine hydrochloride, phentermine and diethylproprion hydrochloride,antidrags stimulants such as aminophylline, theophylline, salbutamol, orciprenaline sulphate and terbutaline sulphate, expectorant drug such as guaiphenesin, cough suppressants such as dextromethorphan and mescaline, mucolytic drags such as carbocisteine, antiseptics such as cetylpyridinium chloride, tyrothricin and chlorhexidine, decongestant drugs such as phenylpropanolamine and pseudoephedrine, hypnotic drags such as dichloralphenazone and nitrazepam,antidrugs Hi blockers such as promethazine theociate, haemopoetic drugs such as ferrous sulphate, folic acid and calcium gluconate, uricosuric drugs such as sulphinpyrazine, allopurinol and probenecid and the like. It is understood that the invention is not restricted to the above medications.

The amount of pharmaceutically active ingredient in the present composition can vary widely, as desired. Preferably, the active ingredient is present in a composition of the present invention in an effective dosage amount. Exemplary of a range that the active ingredient may be present in a composition in accordance with the present invention is from about 0.000001 to about 10 weight %. More preferably, the amount of active ingredient is present in the range of about 0.001 to 5 weight %.

Of course, it should be understood that any suitable phamiaceutically acceptable fonn of the active ingredient can be employed in the compositions of the present invention, i.e., the free base or a phamiaceutically acceptable salt thereof, e.g., levothyroxine sodium salt, etc.

When the phamiaceutically active moiety is levothyroxine sodium, the preferred amount ofthe active moiety in the composition is present in the range of about 0.00005 to about 5 weight %. The more preferred range is from about 0.001 to about 1.0 weight %, and the most preferred range is from about 0.002 to about 0.6 weight % levothyroxine. The minimum amount of levothyroxine can vary, so long as an effective amount is utilized to cause the desired pharmacological effect. Typically, the dosage forms have a content of levothyroxine in the range of about 25 to 300 micrograms per 145 milligram pill for human applications, and about 100 to 800 micrograms per 145 mg pill for veterinary applications.

In accordance with the present invention, a goal of levothyroxine replacement therapy is to achieve and maintain a clinical and biochemical euthyroid state, whereas a goal of suppressive therapy is to inhibit growth and/or function of abnormal thyroid tissue. A dose of levothyroxine that is adequate to achieve these goals depends of course on a variety of factors including the patient's age, body weight, cardiovascular status, concomitant medical conditions, including pregnancy, concomitant medications, and the specific nature ofthe condition being treated. Hence, the following recommendations serve only as dosing guidelines. It should be understood by those versed in this art that dosing should be individualized and adjustments made based on periodic assessment of a patient's clinical response and laboratory parameters.

Preferably, but not necessarily, when using levothyroxine to treat, it should be taken in the morning on an empty stomach, at least one-half hour before any food is eaten. In addition, levothyroxine is preferably taken at least about 4 hours apart from drugs that are known to interfere with its absorption.

Due to the long half-life of levothyroxine, the peak therapeutic effect at a given dose of levothyroxine sodium may not be attained for about 4 to about 6 weeks.

In people older than 50 years, who have been recently treated for hyperthyroidism or who have been hypothyioid for only a short time (such as a few months), the average full replacement dose of levothyroxine sodium is approximately 1.7 mcg/kg/day (e.g., about 100 to about 125 meg/day for a 70 kg adult). Older patients may require less than 1 mcg/kg/day. Levothyroxine sodium doses greater than about 200 meg/day may or may not be required.

For most patients older than 50 years or for patients under 50 years of age with underlying cardiac disease, an initial starling dose of about 25 to about 50 meg/day of levothyroxine sodium is recommended, with gradual increments in dose at about 6 to about 8 week intervals, as needed. The recommended starting dose of levothyroxine sodium in elderly patients with cardiac disease is about 12.5 to about 25 meg/day, with gradual dose increments at about 4 to about 6 week intervals. The levothyroxine sodium dose is generally adjusted in about 12.5 to about 25 meg increments until the patient with primary hypothyroidisni is clinically euthyroid and the serum TSH has normalized.

In patients with severe hypothyroidisni, the recommended initial levothyroxine sodium dose is about 12.5 to about 25 meg/day with increases of about 25 meg/day about every 2 to about 4 weeks, accompanied by clinical and laboratory assessment, until the TSH level is normalized. In patients wim^"secondafy

the levothyroxine sodium dose should be titrated until the patient is clinically euthyroid and the serum free-T level is restored to the upper half of the normal range.

In children, levothyroxine therapy may be instituted at full replacement doses as soon as possible. Levothyroxine compositions ofthe present invention may be administered to infants and children who cannot swallow intact tablets by crushing the tablet and suspending the freshly crashed tablet in a small amount (5-10 mL or 1-2 teaspoons) of water. This suspension can be administered by spoon or dropper. Foods that decrease absorption of levothyroxine, such as soybean infant formula, should not be used for administering levothyroxine sodium tablets.

A recommended starting dose of levothyroxine sodium in newborn infants is about 10 to about 15 mcg/kg/day. A lower starting dose (e.g., about 25 meg/day) may be considered in infants at risk for cardiac failure, and the dose should be increased in 4-6 weeks as needed based on clinical and laboratory response to treatment. In infants with very low (< about 5 mcg/dL) or undetectable serum T₄ concentrations, a recommended initial starting dose is about 50 meg/day of levothyroxine sodium.

As indicated above, levothyroxine therapy is usually initiated at full replacement doses, with the recommended dose per body weight decreasing with age (see Dose Table below). However, in children with chronic or severe hypothyroidisni, an initial dose of about 25 meg/day of levothyroxine sodium is recommended with increments of 25 meg every 2-4 weeks until the desired effect is achieved. Hyperactivity in an older child may be minimized if the starting dose is one-fourth ofthe recommended full replacement dose, and the dose is then increased on a weekly basis by an amount equal to one-fourth the full-recommended replacement dose until the full recommended replacement dose is reached.

Levothyroxine sodium tablets, USP, in accordance with the present invention may be supplied as oval or violin-shaped, color-coded, potency marked tablets in, for example, 12 strengths as indicated in the Strength Table

When the phamiaceutically active moiety is liothyronine sodium, the preferred amount of the active moiety in the composition is present in the range of about 0.000005 to 0.5 weight %. The more preferred range is from about 0.00001 to 0.1 weight %, and the most preferred range is from about 0.00004 to about 0.002 weight % liothyronine. The minimum amount of lyothyronine can vary, so long as an effective amount is utilized to cause the desired pharmacological effect. Typically, the dosage forms have a content of levothyroxine in the range of about 5 to 50 micrograms per 145 milligram pill for human applications.

The β-form microcrystalline cellulose product of the present invention is prepared by forming a wet cake, drying the cake with a drum dryer, then passing the dried product through a 5creen^~6Trnill for ^"sizing which produces a ϊ TJ-sh et hicrocrystalliήe cellulose which has a flat needle shape, as disclosed in U.S. Patent 5,574,150. Such β-sheet microcrystalline product is available from Asahi Chemical of Japan and/or marketed by FMC Company of Newark, Del, under the trademark Ceolus®. The moφhology and perfomiance characteristics of the Ceolus® product are different from those of α - fonn microcellulose products (for example, Avicel® and Emcocel®), and are suitable for preparing the present stabilized pharmaceutical composition.

The amount of β-form microcrystalline product used in the present composition is at least 50 weight % ofthe final composition. Preferably, the amount of β-form microcrystalline product is in the range of about 50 to 99 weight %. Most preferably, the amount of β-form microcrystalline product is in the range of about 60 to 90 weight % ofthe final composition.

Other suitable excipients for the present invention include fillers such as starch, alkaline inorganic salts such as trisodium phosphate, tricalcium phosphate, calcium sulfate and sodium or magnesium carbonate. The fillers can be present in the present composition in the range of about 0 to 50 weight %.

Suitable disintegrating agents include com starch, cross-linked sodium carboxymethylcellulose (crosscamiellose) and cross-linked poly vinyipyrroli done (crospovidone). A preferred disintegrating agent is crosscamiellose. The amount of disintegrating agent used is in the range of about 0 to 50 weight %. Preferably, the disintegrating agent is in the range of about 5 to 40 weight %, more preferably about 10 to about 30 weight %. This is in substantial excess of the recommended levels of such materials. For example, the recommended loading of crosscamiellose is 0.5 to about 2% by weight. However, it has been found that the higher loadings of the disintegrating agents substantially improves the ability of the product to disperse in aqueous media.

Suitable gildents for use in the present invention include colloidal silicon dioxide and talc. The amount of gildent in the present composition is from about 0 to 5 weight %, and the preferred amount is about 0 to 2 weight %.

Suitable lubricants include magnesium and zinc stearate. sodium stearate fumarate and sodium and magnesium lauryl sulfate. A preferred lubricant is magnesium stearate. The amount of lubricant is typically in the range of about 0 to 5 weight %, preferably in the range of about 0.1 to 3 weight %. The dfal pnafmaceutical product is pfepafed by thoroughly interrhixinglhe active moiety and the β-foπn of microcrystalline cellulose, along with other excipients to form the oral dosage. Food grade dyes can also be added. For example, it is common to distinguish dosages of various potency by the color characteristics of such dyes.

As discussed, a preferred immediate release pharmaceutical composition in tablet fonn includes levothyroxine sodium. In a preferred embodiment, the composition includes at least one of, preferably all ofthe following:

a) between from about 0.01 mg/tablet to about 500 mg/tablet levothyroxine sodium (USP), b) between from about 100 mg/tablet to about 110 mg/tablet of microcrystalline β-cellulose, NF (Ceolus) having a bulk density of between from about 0.10 g/cm^" to about 0.35 g/cm³, c) between from about 25mg/tablet to about 50mg/tablet of crosscamiellose sodium, NF (Ac-di-sol); and d) between from about 0.5 mg/tablet to about 5mg/tablet of magnesium stearate, NF.

Preferably, the composition further comprises at least one pharmaceutically acceptable coloring agent.

More particular methods according to the invention provide compositions having less than about 5% total impurities as detemiined by the standard impurity test. Preferably, the method further comprises fonning a tablet, particularly those tablets having a raised violin configuration.

The stabilized oral dosages of thyroid hormone are prepared by forming a trituration of the active moiety (i.e. levothyroxine sodium and/or liothyronine sodium) and β-form microcrystalline cellulose. The trituration is blended with β-foπn microcrystalline cellulose and additional excipients and compressed into oral dosages.

Design of the tableting apparatus is important, in order to maintain consistency from one oral dosage to the next. The fonnulation batches are a blend of solid compositions of various shapes and sizes. Blending is used to achieve a measure of homogeneity. In particular the active thyroid rh^letyis^"desifed ^"to^"be evenly distributed throughout the batch. In a typical 410 kg batch, the amount of active moiety represents less than 1 kg of the total weight. For example, when producing 145 mg tablets with a 300 meg dosage, approximately 0.8 kg of a 410 kg batch is the active moiety. In addition each tablet is formulated to contain 100% label claim potency.

It is typical for compressible medicament tablets to be formed using a 2:1 fill to compression ratio. However, for medicament tablets fonned using the present invention a fill to compression ratio from 3.3:1 to 4:1 is needed to obtain desired tablet density. The β-foπn microcrystalline cellulose has a lower bulk density, as compared to other excipients.

Higher tablet density can be accomplished by adjusting a tableting machine to increase the compression ratio. Tableting machines are commonly known to practitioners in the art and include those available from Manesty and Stokes. It has been found that making such adjustments to the compression ratio results in poor tablet surface finish as well as inconsistent tablet weights. Instead, the design of the tableting dies should be adjusted. It has been determined that during the filling ofthe tableting dies, a minimum of 5-6mm die overfill. In most cases this requires replacement of the usual tableting dies with dies which are an additional 2-3 mm deep.

When using the extra-deep dies and a compression ratio of from 3.3:1 to 4.0:1, consistent weight tablets with good surface finish were produced.

Preferably, the shape of the tablet is configured to increase heat transfer away from the tablet. More preferred tablets have a surface area per tablet of between from about 0.9 in.² to about 0.15 in.², preferably about 0.1 15in.², to assist such heat transfer. Additional tablet configurations are contemplated e.g., tablets that are beveled and/or include a notch. A preferred tablet shape is a raised violin configuration, as shown in Figure IC.

The following examples are given by way of illustration only and are not to be considered limitations of this invention or many apparent variations of which are possible without departing from the spirit or scope thereof. Example 1

Stability Tests

Stability testing was perfoπned on samples ofthe thyroid hormone drug formulation used in manufacturing tablets with an active moiety of levothyroxine sodium. Tests were perforated on direct compression formulations for dosage strength of 25 meg. Example 1 tablets comprise m -Tornϊ mlcrc^rystøllϊhe^" cellulose while ι ^"Control 1 tablets comprise the traditional -for ^: m microcrystalline cellulose. The composition of Example 1 and Control 1 tablets are presented in Table 1 and stability test results in Table 2:

Table 1 - Tablet Formulation for 25mcg Dosages of Levothyroxine Sodium

Table 2 - Stability Test - Potency at 25 ° C - % Label Claim

As seen in Table 2, the stability of phannaceutical fonnulations of the present invention is improved significantly by the use of the β - sheet microcrystalline cellulose. Potency loss of the present invention after 15 months is 3.5 %, versus 16.0 % potency loss experienced in a similar formulation with the α-form microcrystalline cellulose. The average loss in potency per month in the case of the compositions of the present invention was only about 0.2 % per month, aTcompa ed to over 1% per month for the T4 producfs which included β-form microcrystalline cellulose, thus demonstrating a stability which is about 3 to 4 times better than the T4 products which utilized α-form microcrystalline cellulose.

Tableting testing was perfomied on the fonnulation for Example 1 tablets. Initial results with standard die depths provided a relative standard deviation of 2.2 to 3.5% tablet weight. With the use of the herein described extra deep tablet dies, the relative standard deviation is 1.2%. Testing was performed on a Manesty tableting machine with compression ratios of from 3.3:1 to 4.0:1.

Tablet quality is also dependent upon the storage of the β-sheet microcrystalline cellulose. Best results are achieved when the cellulose is received in drums or portable containers instead of bags. The bag fomi suffers from compression during transportation from raw material suppliers. Test results for tableting are presented in attached Exhibit A.

Additional examples of solid dosage formulations are illustrated in Tables 3 and 4. Stability testing data of additional examples are illustrated in Table 5.

Table 3 - Tablet Formulation for Dosages of Levothyroxine Sodium (per tablet)

Table 4 - Tablet Formulation for Dosages of Levothyroxine Sodium (per tablet)

1100 meg Dosage 1112 meg Dosage |300 meg Dosage [Component

Table 5 shows drag stability data for a number ofthe above formulations:

Table 5 - Stability Test - Potency at 25 ° C - % Label Claim

Thus the fomiulations of the present invention provide extreme stability for the levothyroxine activity over an extended shelf life for these phaπnaceutical products. Example^

Dissolution Tests

The following preferred method for testing potency will sometimes be referred to herein s method number: AM-004B

Table 6 - Dissolution Test Procedure

Calculations: Sample Area x 798.86 x Amt. Std. Injected x 100% = % Dissoluted

% Dissoluted Std. Area 776.87 Amt. Samp. Injected

Where 798.86 = molecular weight of Levothyroxine as Sodium Salt

776.87 = molecular weight of Levothyroxine (as Base)

Table 7 - Acceptance Criteria

Table 8 shows comparative dissolution data for all strengths of Levoxyl^® tablets.

Table 8 - Comparative Dissolution Data

-300-raeg— 1 0.1)%— ^' -|-^~ 4.5%- ^" 1 ^2.1% f 91.4% ^{~ "}t^{~™ "} 87.Wo [ 84.0%

Figure 4 depicts graphs showing the mean results for each of the tablet strengths of Levoxyl^® tested. Each point is the mean of three dissolutions, testing 12 tablets per dissolution or n=36. The data is presented as percent of label claim dissoluted vs. dissolution time.

The results demonstrate that the multi-point dissolution profiles for Levoxyl^® tablets are similar across a wide variety of tablet strengths. Moreover, all strengths substantially exceed the requirements for immediate release oral dosage forms (i.e. at least 80% dissoluted with 15 - 20 minutes). In each dosage fomi, these pills were over 90% dissoluted within two and a half minutes.

The extremely rapid dispersion rates for the tablets of the present invention make possible a simplified treatment method for infants or others who have difficulty swallowing pills. In this approach, the appropriate dosage for the patient in question, in an immediate release pill made in accordance with the present invention, is simply mixed with a suitable amount, e.g. 50 - 200 ml, of aqueous fluid, such as water, soft drinks, juice, milk, etc. The immediate release pill is easily dissoluted in the fluid, optionally with stirring or shaking, and simply administered to the patient.

Example 3

Potency Test

The following method for testing potency of the tablets will sometimes be referred to herein as method number: AM-003. Alternatively, the tablet potency can be tested according to method AM-021. Method number: AM-021 is the same as method number: AM-003, except the tablets are dissolved whole without first grinding the tablets into a powder, as with method number: AM-003.

Method Reference:

USP 24 pp. 968-970

Chromatographic Conditions:

Mobile Phase: 65:35:0.05 H20: CAN: H3P04 degassed and filtered; mobile phase composition may be altered to achieve a satisfactory resolution factor. Column:

ACN, 4.6 mm x 25 to 30 cm

Flow Rate:

1.5 ml/minute

Detector:

Deuterium, set at 225 nm

Injection Volume: 100 ml

System Suitability:

Chromatograph 5 replicate injections of the standard preparation. Record the peak responses as directed under "Procedure".

1.0 RSD for the standard replicates must not be more than 2.0% for T₄

2.0 Calculate the resolution factor R on one of the five replicates. The R-value must be greater than or equal lo 5.0 to proceed. See Method QC-009.

Standard Preparation:

Accurately weight 25 mg of USP Levothyroxine RS and transfer to an amber 250-ml volumetric flask. Add approximately 50ml extraction mobile phase. Let stand for 20 minutes with occasional swirling. Sonicate for 30 seconds. Gradually add more extraction solution and repeat sonication until no undissolved particles are observed. Dilute to volume with extraction solution. Mix well. The concentration of T₄ is about 100 μg/ml. Also dissolve an accurately weighed quantity of USP Liothyronine RS to yield about 100 mg/ml, done as above with USP Levothyroxine RS. Label this solution as stock T₃-A. Stock-Standard TJilutiϋrπ —

1. Pipette 10.0 ml stock T₃-A into a 500 ml Type A volumetric flask.

2. Dilute to volume with Mobile Phase for a concentration of about 2 μg/ml. Mix well and label this solution as std. T₃-B.

3. Pipette 50.0 ml each from the T₄ and T₃-B stock standards and transfer into a 500-ml Type A volumetric flask

Dilute to volume with mobile phase and mix well. Label this standard as T₃/ T₄ working standard. The concentration of the working standard should be about 0.2 μg/ml T₃ and 10.0 μg/ l T_4.

Hols:

Concentrations of Levothyroxine and Liothyronine require adjustments for water content.

Assay Preparation:

Weigh not less than the specified tablet quantity and calculate the average tablet weight. Crash tablets into a uniform fine powder with a mortar and pestle. Tare a polypropylene weigh boat.

Accurately weigh (to 0.1 mg) a portion of the powder into the tared weigh boat using a preconditioned stainless steel scoop or spatula (either Teflon coated or uncoated). The spatula or scoop is preconditioned by dipping it into the powder. Use the Sample Calculation below to achieve 50 ml of a 10 μg/ml assay solution.

Record the sample weight taken. Carefully transfer the sample into an Erlenmeyer flask, reweigh the weigh boat and subtract the residual weight from the weight taken to obtain the actual sample weight. Pipette 50 ml of mobile phase into the flask. Cover the flask with parafilm, sonicate for approximately 10 seconds and vortex for approximately 235 seconds at a speed of 6 or greater. Observe sample preparation, and if clumping is noted, repeat the sonication and/or vortex steps. Centrifuge (~3,000φm) for NLT 1 minute until a clear supernatant is achieved. Transfer a portion ofthe supernatant to an auto sampler vial.

For In-Process granulation analysis, use the theoretical tablet weight (0.1455 g) in place of (weight of tablets/number of tablets) in the fonnula below. Sample Calculation:

Weight of Tablets X lOμg X 50ml = Amount to Weight Out per Assay Number of Tablets ml Dose (μg)

Procedure:

Separately inject 100 μl of the sample onto the column. Record the responses of the analyte peak and calculate % label claim as follows.

Calculations:

Sample Area x Std cone, (μg) x 50 ml x avg. tablet weight in g x 798.86 = μg/dose x 100 = % Label Claim

Standard Area (ml) Actual Sample wt in g 776.87 Label Claim

Where 798.86 = molecular weight of Levothyroxine as the Sodium Salt

776.87 = molecular weight of Levothyroxine Standard Base

Results:

Figures 5A and 5B show HPLC chromatograms of levothyroxine and liothyronine controls (T3/T4 working standard, shown in Figure 5A) and an experimental sample made in accordance with the present invention as described above.(Figure 5B). The peaks in both chromatograms in the area of 1.325 to 3.1 correspond to materials in the solvent. The peak at about 7.2 in Fig. 5A shows the presence of T3. Fig. 5B shows the absence of T3, as well as the absence of other related products or degradation products of levothyroxine.

Example 4

Hardness Test

The following preferred method for testing tablet hardness will sometimes be referred to herein as method number: QC-005 Table ? - βC-VOS BaJdness Test Procedure

Generally the hardness of the pills lies between about 6.0 and about 14.0 kiloponds. Preferably the pill hardness is from about 9 to about 13 kiloponds. Typical results of products made in accordance with the present invention are about 9.3, 11.3, 9.8, 10.2, 12.3, etc. Pharmaceutical tablets which incorporate granulated active ingredient are typically much higher in hardness, which may add to the difficulty of dissolving or dissoluting them. Pills which are lower in hardness generally present more problems of pill fragmentation during handling and storage.

Example 5

Impurity Tests

The following preferred method for testing tablet impurities is sometimes referenced herein as method number: SA-004

Table 10 - SA 004 Impurity Test Procedure

Method Reference: Biochemie Method No. 1417-6, Report JMI-DP-002

Equipment: HPLC with a gradient system and a detector at a wavelength of 225 nm

Reagents: Acetonitrile, HPLC grade

Methanol, HPLC grade

Water, HPLC grade Sδ lhϊm Hyϊ3foxlde7 ACS reagent grade

Sodium Hydroxide 0.1 solution: Dissolve 40g of NaOH pellets in 1000 ml

HPLC grade water. Store in a plastic container.

Phosphoric acid, 85% reagent grade

Diiodothyronine reference material

Liothyronine RS USP reference material

Levothyroxine RS USP reference material

Triiodothyroacetic acid reference material

Tetraiodothyroacetic acid reference material

Solvent 1: To 100.0 ml of 0.1 N Sodium Hydroxide solution add a 1: 1 V/V mixture of methanol and water to make 1000 ml.

Solvent 2: 77:23:0.1 H2): CANACN: H3PO4; Degassed and filtered; mobile phase composition a may be altered to achieve a satisfactory resolution factor.

Extraction solution: Pipette 50 ml of solvent 1 into a 1000 ml volumetric flask dilute to volume with solvent 2, stopper and mix well.

Chromatography Nucleosil 100-lOCN, 250 mm long, 4.6 mm internal diameter, at ambient

Column: temperature

System: Gradient Elution

Mobile phase A: 1000: 1 H2O:H3PO4 V/V

Mobile phase B: Acetonitrile

Gradient program:

Time min

% of mobile phase A

% of mobile phase B

0

77 23

13

77 23

15 65 35

24 65

35

26

77 23

Flow rate: 1.5 ml/min.

Injection Volume: 100 up: next injection after approx. 40 min. Detector: UV, 225 nm System Suitability: Chromatograph 5 replicate injections of the Reference I Standard preparation, chfomalδgrapTi^ replicate irijectiόhs oTme^~Reference II Standard. Record the peak responses as directed under "Procedure". An extraction blank is to be run after the standards.

1. The RSD must not be greater than 2.0% for each of the impurities in the standard reference solution I.

2. The resolution factor between liothyronine and levothyroxine in thestandard reference solution I must not be less than 5.0.

3. The Signal to Noise ratio must not be less than 5/1 for levothyroxine and impurities in the chromatogram obtained with standard reference solution II.

4. A peak of monochlorotriiodothyronine may occur just before the levothyroxine peak. Make sure that the degree of separation between this peak and of levothyroxine is at least sufficient to permit separate evaluations. Monochlorotriiodothyronine reference material is not available to be purchase by any vendor. Any calculation of monochlorotriiodothyronine impurity will be done by its retention time.

Standards 1. Stock Standard Reference Solution: Preparation: Accurately weigh 10 mg +/- 0.1 mg of each Diiodothyronine, Liothyronine, Levothyroxine, Triiodothyroacetic acid and Tetraiodthyroacetic acid reference standards into a 100ml volumetric flask. Dissolve in Solvent 1 and dilute to volume, stopper and mix well. The concentration of each component will be approximately lOOmcg/mlL.

2. Standard Reference solution I:

Pipette 5.0 ml of Stock Standard Reference Solution into a 100 ml volumetric flask, dilute to volume with Solvent 2, stopper and mix well. The Final concentration of each component will be approximately 5mcg/mlL.

3. Standard Reference solution II (0.05%):

Pipette 2.0 ml of Standard Reference Solution I into a 100 ml volumetric flask, dilute to volume with Solvent 2, stopper and mix well. The final concentration of each component will be approximately 0.1 mcg/mlL.100

Test Preparation: Crush not less than 20 tablets. Tare a 250 ml Erlenmeyer flask. Accurately weigh to the nearest 0.1 mg an equivalent of 500 meg of levothyroxine sodium (+/- 10%) into a 250 ml Erlenmeyer flask. Pipette 100.0 meg of the Extraction solution into the flask cover the flask with parafilm, sonicate, vortex and then centrifuge the solution for 1 minute each. The final concentration ofthe sample will be approximately 5 mcg/ml of levothyroxine.

To calculate the amount to weigh for the test preparation use the following equation:

500 meg X 0.1450g* Amount to weight for the test prep tablet label claim (meg)

* where 0.1450 g = theoretical tablet weight

Note: Analyst must keep all materials use in performing this assay until the results are calculated, checked, and recorded and it is verified that the test is acceptable. This includes the crush, the Erlenmeyer flask with Extraction solutibn,lhe centTifύgefiibe an e aύlδ-sampler vial. Tf me ahalysls s running overnight, these materials should be sealed with parafilm and saved until results are obtained and the results are deemed acceptable

Procedure: 1. Separately inject lOOμl ofthe sample preparation onto the column. Record the response ofthe analyte peaks and the calculate % w/w using the equations below.

2. The chromatogram may need to be reprocessed to obtain optimal integration. A copy ofthe sample chromatograph is to be attached to the analytical packet.

3. Peaks on the sample chromatograph with areas less than a signal ratio of 5/1 will be considered none detected.

Calculations:

Diiodothyronine:

Sample area X Std Cone, fmcgl X 100ml X 100% 1.11^s = % w/w Std. Area ml Wsimpl (g) 1000000 mcg/g or

Sample area X Std. Cone, (mcg^ X QM X 1.11 * = %w/w *where 1.1 1 is a correction factor

Triiodothyroacetic Acid:

Sample area X Std Cone, (meg) X 100ml X 100% % w/w

Std. Area ml Wsimpl (g) 1000000 mcg/g or

Sample area X Std. Cone, (meg) X 0.01 %w/w Std area ml Wsimpl (g)

Tetraiodothyroacetic Acid:

Sample area X Std Cone, (mcgl X 100ml X 100% x l .l6* = % w/w

Std. Area ml Wsimpl (g) 1000000 mcg/g or Sample-area ^"X— StαrCόne: Tfficgl QM ^{" " " "}X 1.15* =^~' Yow/ Std area ml Wsimpl (g)

*where 1.16 is a correction factor

Limit of Detection (LOD) Values

Calculation of the theoretical area for 0.05% of levothyroxine sodium, based on the initial amount in mg of levathyroxine sodium in the whole sample weight.

(Area rs II)(A)(10.0) = Theoretical area for 0.05% of levothyroxine Na, based

(.05) (T₄std st.)(P)(l .0283) on the actual weight

Where: Area_rs -is the average area ofthe levothyroxine in the Standard reference solution II A = is the initial weight of levothyroxine Na in mg represented by the sample weight. This is calculated by using this equation: = sample weight (g) X claim T₄in meg

0.1450g X 1000 mcg/mg 10.0 = theoretical initial weight of the Levothyroxine USP reference standard 0.500 = is the theoretical initial weight of the Levothyroxine NA to be tested, in mg T₄ std. Wt. = the initial weight ofthe levothyroxine USP standard in mg P = the purity of the levothyroxine Na USP standard (%purity/100%) 1.0283 = conversion of levothyroxine into levothyroxine sodium

Greatest unknown impurity (individually):

(Area i,_ιmunlv T₄std wt mg)(l .0283) (PI (100) = impurity (%) (Area ref std I) (A) (2000)

Where: Area ,_mpunty is the area of the greatest unknown impurity in the test solution with an area greater than the theoretical area for 0.05% of the levothyroxine Na taken into account.

1.0283 = conversion of levothyroxine into levothyroxine sodium P = the purity of the levothyroxine Na USP standard (% purity/ 100%) 100 is the dilution of the test solution

Area ref std I is the area of the levothyroxine in the standard reference solution I A = is the initial weight of levothyroxine Na in mg represented by the sample weight. This is calculated by using this equation: = sample weight (g) X claim T4 in meg

0.1450g X lOOO mcg/mg

2000 is the dilution ofthe reference solution. Total of other Unknown Impurities:

(Sum area impurities^') (T4 std wt mg) (1.0283) (P (100) = Total Unknown impurities (%)

(are ref std I) (A) (2000) Where: Sum area impurity is the sum ofthe areas of all the other unknown impurities in the test solution

(only areas that are greater than the theoretical area for 0.05% ofthe levothryoxine sodium taken into account)

T4 std. wt. = the initial weight of the levothyroxine USP standard in mg

1.0283 = conversion of levothyroxine into levothyroxine sodium

P = the purity of the levothyroxine Na USP standard (% pursity/100%)

100 is the dilution of the test solution

Area ref std I is the area ofthe levothyroxine in the standard reference solution I

A = is the initial weight of levothyroxine Na in mg represented by the sample weight.

This is calculated by using this equation: = sample weight (g) X claim T4 in meg

0.1450g X 100 mcg/mg 2000 is the dilution ofthe reference solution.

Results of the test are shown in Figures 6A and 6B. Figure 6A shows an example of a chromatogram of Standard Reference Solution II, with exemplary peaks at about 5.4 for diiodo-1- thyronine, 8.4 for liothryonine, 12.8 for levothyroxine, 19.3 for triiodo thyroacetic acid, and 21.9 for tetraiodo thyroacetic acid. Figure 6B shows results of an experimental sample of levothyroxine sodium, made in accordance with this invention. As can be seen, the sample had substantially only levothyroxine, with insignificant impurities.

Example 6

Liothyronine (T3) Tests

The following preferred method for testing for Triiodothyronine is sometimes referenced herein as method number: QC-001

Table 11 - QC - 001 T3 Test Procedure

Method Reference USP 24 p. 968-970

Chromatographic 65:35:0.05 H₂O:CACN.Η₃Pθ₄ degassed and filtered; mobile phase

Conditions: composition may be altered to achieve a satisfactory resolution factor.

Mobile Phase:

Column: CN, 4.6 mm x 25 to 30 cm

Flow Rate: 2.0 minute/minute DeϊecforT Deuterium, seYaf 225 nm Injection Volume: 100 μL System Suitability: Chromatograph 5 replicate injections of the standard preparation. Record the peak responses as directed under "Procedure".

1.0 RSD for the standard replicates must not be more than 2.0% for T₄

2.0 Calculate the resolution factor (R) on one of the five replicates.

The R value must be greater than or equal to proceed. See Method

QC-009.

Standard Preparation: Accurately weigh 25 mg of USP Levothyroxine RS and transfer to a clear 250-mlL volumetric flask. Pipette 87.5 ml minute of acetonitrile in the flask. Swirl and then sonicate for less than a minute. Add portions of HPLC grade water to the flask with swirling and sonicating until the material has gone into solution. Be sure that there is no particulate material present. Do not dilute to volume at this point. The solution may be cold. Place into a room temperature water bath for ten minutes to allow the sample to warm to ambient temperature. Dilute to volume with HPLC grade water. Mix well. Label this solution as stock T₄. The concentration of T₄ is about 100 μg/ml.

Also dissolve an accurately weighed quantity of USP Liothyronine RS to yield about 100 μg/minute, done as above with USP Levothyroxine RS. Label this solution as stock T₃-A.

Stock Standard dilution:

1. Pipette 10.0 ml stock T₃-A into a 500-mlL Type A volumetric flask.

2. Dilute to volume with Mobile Phase for a concentration of about 2 μg/ml. Mix well and label this solution as stock std. c-B.

3. Pipette 50.0 ml each from the T₄ and T₃ stock standards and transfer into 500-mlL Type A volumetric flask.

Dilute to volume with mobile phase and mix well. Label this standard as T₃/T₄ working standard. The concentration ofthe working standard should be about 0.2 μg/ml T₃ and 10.0 μg/ml T₄.

Assay Preparation: Weigh and crush not less than the specified tablet quantity and calculate the average tablet weight. Tare a polypropylene weigh boat.

Accurately weigh (to 0.1 mg) a portion ofthe powder into the tared weigh boat using a preconditioned stainless steel scoop or spatula (either Teflon coated or uncoated). The spatula or scoop is preconditioned by dipping it into the power. Use the Sample Calculation below to achieve 50 ml of a 10 μg/ml assay solution.

Record the sample weight taken. Carefully transfer the sample into an Erlenmeyer flask, reweigh the weigh boat and subtract the residual weight from the weight taken to obtain the actual sample weight. Pipette 50 ml of mobile phase into the flask. Cover the flask with parafilm, sonicate for approximately 10 seconds and vortex for approximately 35 seconds at a speed of 6 or greater. Observe sample preparation, and if clumping is noted fepeaTfhe sδnϊcahόnltha/όr vbrte sϊepsT Centrifuge (~3 )δθ rpm) for NLT 1 minute until a clear supernatant is achieved. Transfer a portion of the supernatant to an autosampler vial.

For In-Process granulation analysis, use the theoretical tablet weight (0.1455 g) in place of (weight of tablets/number of tablets) in the formula below.

Note Analyst must keep all materials used in performing this assay until the results are calculated, checked, and recorded, and it is verified that the test is acceptable. This includes the crush, the Erlenmeyer flask with Mobile Phase, the centrifuge tube and the autosampler vial. If the analysis is running overnight, these materials should be sealed with parafilm and saved until results are obtained and the result is deemed acceptable.

Sample Calculation: Weight of Tablets X 10 μg/ml X 50 ml = Amount to Weigh Out per

Assay Number of Tablets Dose (μg)

Procedure: Separately inject 100 μl of the sample onto the column. Record the responses ofthe analyte peak.

Calculations: Calculate the content of liothyronine using the following formula:

Sample T₃ Area X Std T₃ cone, (μg) x 50 ml = μg T₃ Standard T₃ Area (ml)

The specification is NGT 2.0% liothyronine calculated as follows:

Amt T, Assayed fug) x 100 = % LIOTHYRONINE

Amt T₄ Assayed (ug)*

This number is calculated using the T₄ potency results as follows:

Sample T^ Area X Std T_ cone, (μg) x 50 ml x 798.86 = μg T₄ Standard T₄ Area (ml) 776.87 where 798.86 - molecular weight of Levothyroxine as the Sodium Salt 776.87 = molecular weight of Levothyroxine Standard Base

NOTE: If the single active ingredient comprises 50% or more, by weight, of the dosage unit, use Method A; otherwise use Method B.

METHOD: USP 24 <905> pp. 2000-2002.

METHOD A: Content Uniformity as Determined by Weight Variation:

Weight accurately 10 tablets, individually. From the results ofthe average potency of the active ingredient determined for the product (using the assay methods as stated in the individual monograph) calculate the content of active ingredient in each ofthe 10 tablets. CALCULATIONS: Individual = (Avg. potency) (Individual Wt.) Potency Avg. tablet weight

NOTE: If the active ingredient(s) are less than 50% by weight ofthe tablet content, refer to the individual test method for potency for those products.

METHOD B: Content Uniformity as Determined by Direct Assay of Active Ingredient: For Levothyroxine Sodium tablets the following procedure is followed. Individually weigh 10 tablets. Place the 10 individual tablets into round bottomed test tubes or flasks of the appropriate size as outlined in the chart below. Add the appropriate volume of extraction mobile comprised of water, acetonitrile, and phosphoric acid (65:35::0.05) to each test tube or flask as indicated in the chart below. Note: All test tubes are to be capped with screw on caps and all flasks are to be covered with parafilm as soon as mobile phase is added. Allow to stand at room temperature until the tablet completely crumbles. Secure all samples in a wrist action shaker. Test tubes are to be secured horizontally. Erlenmeyer flasks are to be secured vertically. Set the wrist shaker to the setting specified in the table. Shake sample for 3 minutes. Transfer about 10 ml ofthe sample preparation (or the entirety of smaller samples) to a centrifuge tube. Centrifuge samples for 1 minute at about 3000 φm. Transfer samples to autosampler vials using disposable Pasteur pipettes. Utilize the HPLC Method for levothyroxine separation (AM-003) for obtaining dosage uniformity, sample area, and standard area results.

CALCULATIONS: Dosage Uniformity Result (% Label Claim)

798.86 X Area of Sample X Cone, of Std. X 100 = % Potency

776.87 Area of Std. Cone. Of Sample (see chart below)

SPECIFICATIONS FOR METHOD A OR METHOD B

S-l The % active ingredient for 10 tablets tested must fall in the range of 85.0% - 1 15.0% and the RSD ofthe 10 tablets must not exceed 6.0%.

NOTE: If 1 unit in S-l fails to meet either ofthe specifications, but is no outside the range of

15% - 125%>, test 20 more units and proceed to S-2. S-2 When n = 30, NGT one unit outside 85.0-1 15.0%, none outside 75.0-125.0% and RSD

NGT 7.80%.

Results:

Results for a variety of dosages, using a sample size of 120 pills, are shown in Table 12: Table 12 - Dosage Consistency - 120 pill samples

The results confirm an extremely low amount of variability in active material content between the 120 pills tested. Generally the variability for a 120 pill sample should be between about 90 and about 110 % of claimed activity, preferably between about 95 % and about 105%. The RSD for a 120 pill sample should not be greater than 5%, and preferably is less than 3%.

Example 7

Levothyroxine Sodium Release Specification and Analytical Methods

The specifications for levothyroxine sodium tablets are stated in: USP 24 page 969-970 and Supplement 1 page 2638. The additional requirements are in place to ensure the tablet appearance, for the individual tablet strengths, is correct and the physical characteristics ensure a quality tablet.

A. Analytical Methods:

All the test methods utilized in the testing of levothyroxine sodium meet USP system suitability requirements. All Levoxyl^® batches are tested for confoπnance to the following specifications. The Table 13 below lists the test parameter, specification and the test method employed.

Table 13 - USP Specifications

Additional Requirements:

Example 8

Bioavailability determination of Two Levothyroxine formulations

The following example was performed along lines of a 1999 FDA publication entitled ln- Vivo Pharmacokinetics and Bioavailability Studies and In-Vitro Dissolution Testing for Levothyroxine Sodium Tablets. The example includes the following two studies.

Study 1. Single-Dose Bioavailability Study

The objective of the study was to detennine the bioavailability of Levoxy 1l®* relative to a reference (oral solution) under fasting conditions.

Study 2: Dosage-Form Equivalence Study

The objective of the study was to detennine the dosage-form bioequivalence between three different strengths of Levoxyl^® tablets (low, middle and high range).

Study Objective;

To determine the bioavailability of levothyroxine sodium (Levoxyl^®) 0.3 mg tablets manufactured by JONES PHARMA INCORPORATED, relative to Knoll Phannaceutical Company's levothyroxine sodium 200 g (Synthroid^®) injection given as an oral solution following a single 0.6mg dose.

Study Methodology:

Single-dose, randomized, open-label, two-way crossover design Protocol Reference:

Guidance for Industry: In Vivo Pharmacokinetics and Bioavailability Studies and In Vitro Dissolution Testing for Levothyroxine Sodium Tablets (June 1999).

Number of Subjects:

A total of 30 subjects were enrolled in the study, and 27 subjects completed the study. All 30 subjects were included in the safety analysis and 27 subjects who completed the study were included in the phaπnacokinetic analyses.

Diagnosis and Main Criteria for Inclusion:

All subjects enrolled in this study were judged by the investigator to be healthy volunteers who met all inclusion and exclusion criteria.

Test Product, Dose. Duration. Mode of Administration, and Batch Number:

The test product was levothyroxine sodium (Levoxyl^®) 2 X 0.3mg tablets administered as a single oral dose. The batch number utilized in this study was TT26.

Reference Product. Dose. Duration. Mode of Administration, and Batch Number:

The reference product was levothyroxine sodium (Synthroid^®) 2 X 500 μg injection vials (Knoll Phamiaceutical Company) reconstituted and 600 μg administered orally. The reference product used was the 500 μg injection instead of 200 μg due to the unavailability of sufficient quantities of 200 μg injection to conduct the study. The batch number utilized in this study was 80130028.

Criteria for Evaluation: Pharmacokinetics:

Phaπnacokinetic assessment consisted of the determination of total (bound + free) T4 and T3 concentrations in serum at specified time points following drug administration. From the serum data, the parameters AUC(O-t), Cmax, and Tmax were calculated. Safety:

Safety assessment included vital signs, clinical laboratory evaluation (including

TSH), physical examination, and adverse events (AEs) assessment.

Statistical Methods Pharmacokinetics:

Descriptive statistics (arithmetic mean, standard deviation (SD), coefficient of variation (CV), standard error ofthe mean (SE), sample size (N), minimum, and maximum) were provided for all pharmacokinetic parameters. The effects of baseline and baseline-by treatment interaction were evaluated using a parametric (normal-theory) general linear model (ANCOVA) with treatment, period, sequence, subject within sequence, In(baseline), and interaction between In (baseline) and treatment as factors, applied to the In-transformed phaπnacokinetic parameters and Cmax. In the absence of significant In(baseline) and interaction between In(baseline) and treatment, these parameters were removed from the model. The two one-sided hypotheses were tested at the 5% level of significance for In[AUC(0-t)] and In(Cmax) by constructing 90% confidence intervals for the ratio of Treatment A to Treatment

Safety:

Frequency counts of all subjects enrolled in the study, completing the study, and discontinuing early were tabulated. Descriptive statistics were calculated for continuous demographic variables, and frequency counts were tabulated for categorical demographic variables for each gender and overall.

AEs were coded using the 5^th Edition of the COSTART dictionary. AEs were summarized by the number and percentage of subjects experiencing each coded event. A summary of the total number of each coded event and as a percentage of total AEs was also provided.

Laboratory summary tables included descriptive statistics for continuous serum chemistry and hematology results at each time point. Out-of-range values were listed by subject for each laboratory parameter. Descτiptive^"^tatϊslics^{^}Tof vital sϊgnlneasurehiefits ^"at each time point arid ^"change from baseline to each time point were calculated by treatment group. Shifts from screening to post study results for physical examinations were tabulated.

Pharmacokinetic Results - T4:

ANCOVA analyses indicated that the effects of In(baseline) and interaction between In(baseline) and treatment were not significant. Thus, these factors were removed from the general linear model and an ANOVA with treatment, period, sequence, and subject within sequence was applied to the In-transformed Cmax and AUC(O-t) parameters. The arithmetic means of serum T4 phamiacokinetic parameters for Treatments A and B and the statistical comparison for In-transfonned parameters are summarized in the following table.

Summary of the Pharmacokinetic Parameters of Serum T4 for Treatments A and B

* Treatment A = 2 X 0.3mg Levoxyl Tablets: test

**Treatment B = 0.6mg Synthroid Reconstitute Oral Solution: reference

Pharmacokinetics Results - T3:

ANCOVA analyses indicated that the effects of In(baseline) and interaction between

In(baseline) and treatment were not significant and were removed from the ANOVA model, except for In(baseline) on In(Cmax) which was significant and was kept in the model. An

ANOVA with treatment, period, sequence, and subject within sequence, and In(baseline), when significant, was applied to the In-transformed Cmax and AUC(O-t) parameters. The arithmetic means of serum T3 pharmacokinetic parameters for Treatments A and B and the statistical comparison for In-transfonned parameters are summarized in the following table. lSummary^"oTllιe PharmacokineficTarameters of Serum T3 for Treatments A and B

* Treatment A = 2 X 0.3mg Levoxyl Tablets: test

**Treatment B = 0.6mg Synthroid Reconstitute Oral Solution: reference

Comparison of total T4 and T3 pharmacokinetics following administration of Levoxyl^® (Treatment A, test formulation) and Synthroid (Treatment B, reference formulation) indicated that the test fomiulation met the requirements for bioequivalence with the reference fomiulation.

The 90% confidence intervals for the comparisons of In(Cmax) and In[AUC(0-t)] for T4 and T3 were within the 80% to 125% range reguired for bioequivalence.

In regard to subject safety, both treatments appeared to be equally safe and well tolerated.

Example 9

Bioavailability Study To Assess Single Dose Bioequivalence of Three Strengths of Levothyroxine

The following example was performed to detemiine the dosage-form bioequivalence between three different strengths of levothyroxine sodium (Levoxyl^®) tablets following a single 600 meg dose.

Sfudy Methodology:

Single-dose, randomized, open-label, three-way crossover design.

Protocol Reference: tαuιdS^ήce^"T r^ndustfy: ^""In^" Vivc^hafmacc1dn^f c ^tfd Εic^valIaT lϊty^{^"}^tu3ϊes^" and Th Vitro Dissolution Testing for Levothyroxine Sodium Tablets (June 1999). This protocol was submitted in IND 59,177.

Number of Subjects:

A total of 28 subjects were enrolled in the study, and 24 subjects completed the study. All 28 subjects were included in the safety analysis and 24 subjects who completed the study were included in the pharmacokinetic analyses.

Diagnosis and Main Criteria for Inclusion:

All subjects enrolled in this study were judged by the investigator to be healthy volunteers who met all inclusion and exclusion criteria.

Test Product. Dose. Duration. Mode of Administration, and Batch Number:

Subjects randomized to Treatment A received a single oral dose of 12 X 50 meg levothyroxine sodium (Levoxyl^®) tablets, Lot No. TT24. Subjects randomized to Treatment B received 6 X 100 meg levothyroxine sodium (Levoxyl ) tablets, Lot No.TT25. Subjects randomized to Treatment C received 2 X 300 meg levothyroxine sodium (Levoxyl^®) tablets, Lot No. TT26. Test products were manufactured by JMI-Daniels, a subsidiary of Jones Pharma Incoφorated.

Pharmacokinetics:

Pharmacokinetic assessment consisted ofthe determination of total (bound + free) T4 and T3 concentrations in serum at specified time points following drag administration. From the serum data, the parameters AUC(O-t), Cmax, and Tmax were calculated.

Safety: Safely

Tirig ^" vital ^"signsT clinical ^'laboratory measurements, thyroid-stimulating hormone (TSH), physical examination, electrocardiogram (ECG), and adverse events (AEs).

Statistical Methods. Pharmacokinetics:

Descriptive statistics (arithmetic mean, standard deviation (SD), coefficient of variation (CV), standard error of the mean (SEM), sample size (N), minimum, and maximum) were provided for all pharmacokinetic parameters. A parametric (normal-theory) general linear model with treatment, period, sequence, and subject within sequence as factors was applied to the In- transformed Cmax and AUC(O-t). The two one-sided hypotheses were tested at the 5% level of significance for In[AUC(0-t)] and ln(Cmax) by constructing 90% confidence intervals for the ratios of Treatment A to Treatment B, Treatment A to Treatment C, and Treatment B to Treatment C.

Safety:

Frequency counts of all subjects enrolled in the study, completing the study, and discontinuing early were tabulated. Descriptive statistics were calculated for continuous demographic variables, and frequency counts were tabulated for categorical demographic variables for each gender and overall.

AEs were coded using the 5 Edition of the COSTART dictionary. AEs were summarized by the number and percentage of subjects experiencing each coded event. A summary of the total number of each coded event and as a percentage of total AEs was also provided. Laboratory summary tables included descriptive statistics for continuous serum chemistry and hematology results at each time point. Out-of-range values were listed by subject for each laboratory parameter. Descriptive statistics for vital sign measurements at each time point and change from baseline to each time point were calculated by treatment group. Shifts from screening to post study results for physical examinations were tabulated.

Pharmacokinetic Resulta - T4: Trie-arl mefic mearis^~bT serum T4 piarmacόΗnetic parameters forTreatments A and B and the statistical comparison for the In-transformed parameters are summarized in the following table.

Summary of the Pharmacokinetic Parameters of Serum T4 for Treatments A and B

* Treatment A = 12 X 50 meg Levoxyl^® Tablets **Treatment B = 6 X 100 meg Levoxyl^® Tablets

The arithmetic means of serum T4 pharmacokinetic parameters for Treatments A and C and the statistical comparison for the In-transfonned parameters are summarized in the following table.

Summary of the Pharmacokinetic Parameters of Serum T4 for Treatments A and C

* Treatment A = 12 X 50 meg Levoxyl^® Tablets ^♦♦Treatment C = 2 X 300 meg Levoxyl^® Tablets

The arithmetic means of serum T4 pharmacokinetic parameters for Treatments B and C and the statistical comparison for the In-transformed parameters are summarized in the following table.

Pharmacokinetic Results - T4 (Continued):

Summary of the Pharmacokinetic Parameters of Serum T4 for Treatments B and C

* Treatment B = 6 X 100 meg Levoxyl^® Tablets ^♦♦Treatment C = 2 X 300 meg Levoxyl^® Tablets

Pharmacokinetic Results - T3:

The arithmetic means of seram T3 pharmacokinetic parameters for Treatments A and B and the statistical comparison for the In-transformed parameters are summarized in the following table. Summary Ωιl^harmac^ϊn^tIc^{^}Paraiτneters of Serum T3 for Treatments A and B

* Treatment A = 12 X 50 meg Levoxyl Tablets ^♦♦Treatment B = 6 X 100 meg Levoxyl^® Tablets

The arithmetic means of seram T3 pharmacokinetic parameters for Treatments A and C and the statistical comparison for the In-transfonned parameters are summarized in the following table. Pharmacokinetic Results - T3 (Continued):

Summary of the Pharmacokinetic Parameters of Serum T3 for Treatments A and C

^♦ Treatment A = 12 X 50 meg Levoxyl^® Tablets ^♦♦Treatment C = 2 X 300 meg Levoxyl^® Tablets

The arithmetic means of serum T3 pharmacokinetic parameters for Treatments B and C and the statistical comparison for the In-transfonned parameters are summarized in the following table. Summary of the Pharmacokinetic Parameters of Serum T3 for Treatments B and C

Treatment B = 6 X 100 meg Levoxyl Tablets

®

^♦♦Treatment C = 2 X 300 meg Levoxyϊ^* Tablets

Safety Results:

There was a total of 59 treatment-emergent AEs reported by 15 (54%) of the 28 subjects dosed with study treatment. Incidence of AEs was similar across treatments. Headache was the most frequently reported event. The majority of the AEs were mild in intensity. There was one subject who experienced a serious adverse event of chest pain, considered by the Investigator to be unrelated to treatment. No trends were noted in vital signs, clinical laboratory results, or ECGs to suggest treatment-related differences.

Comparison of total T4 and T3 pharmacokinetics following administration of 12 X 50 meg Levoxyl^® tablets (Treatment A) and 6 X 100 meg Levoxyl^® tablets (Treatment B) indicated that the two formulations met the requirements for bioequivalence. The 90% confidence intervals for the comparisons of In(Cmax) and In[AUC(0-t)] for T4 and T3 were within the 80% to 125%) range required for bioequivalence.

Comparison of total T4 and T3 phaπnacokinetics following administration of 12 X 50 meg Levoxyl^® tablets (Treatment A) and 2 X 300 meg Levoxyl^® tablets (Treatment C) indicated that the two fomiulations met the requirements for bioequivalence. The 90% confidence intervals for the comparisons of In(Cmax) and In[AUC(0-t)] for T4 and T3 were within the 80% to 125%o range required for bioequivalence.

Comparison of total T4 and T3 pharmacokinetics following administration of 6 X 100 meg Levoxyl^® tablets (Treatment B) and 2 X 300 meg Levoxyl^® tablets (Treatment C) indicated

intervals for the comparisons of In(Cmax) and In[AUC(0-t)] for T4 and T3 were within the 80% to 125% range required for bioequivalence.

The test formulations appear to be safe and generally well tolerated when given to healthy adult volunteers.

Example 10

Levothyroxine sodium (Levoxyl®) Tablet Compositions

The following preferred levothroxine sodium compositions in tablet fomi were made along lines disclosed herein.

Levoxyl® 25 meg Tablets

Color: orange; Markings: (front) dp/25 (back) LEVOXYL®

Levoxyl® 50 meg Tablets

Color: white; Markings: (front) dp/50 (back) LEVOXYL®

Levoxyl® 75 meg Tablets

Color: purple; Markings: (front) dp/75 (back) LEVOXYL®

Levoxyl® 88 meg Tablets

Color: olive; Markings: (front) dp/88 (back) LEVOXYL®

Levoxyl® 100 meg Tablets

Color: yellow; Markings: (front) dp/100 (back) LEVOXYL®

Levoxyl® 112 meg Tablets

Color: rose; Markings: (front) dp/112 (back) LEVOXYL®

Lake Blend # LB-1617 (Blend of D&C Yellow # 10 0.080 mg and FD&C Red # 40)

Magnesium Stearate, NF 1.018 mg

Levoxyl® 137 meg Tablets

Color: dark blue; Markings: (front) dp/137 (back) LEVOXYL®

Levoxyl® 150 meg Tablets

Color: blue; Markings: (front) dp/150 (back) LEVOXYL®

Levoxyl® 175 meg Tablets

Color: turquoise; Markings: (front) dp/175 (back) LEVOXYL®

Levoxyl® 200 meg Tablets

Color: pink; Markings: (front) dp/200 (back) LEVOXYL®

Levoxyl® 300 meg Tablets

Color: green; Markings: (front) dp/300 (back) LEVOXYL®

While the present invention has been described in the context of preferred embodiments and examples, it will be readily apparent to those skilled in the art that other modifications and variations can be made therein without departing from the spirit or scope of the present invention. For example, the active moiety levothyroxine sodium can be changed to liothyronine sodium and similar products and still be considered as part of the claimed invention. Accordingly, it is not Intended that the present invention be limited to the specifics of the foregoing description of the preferred embodiments and examples, but rather as being limited only by the scope of the invention as defined In the claims appended hereto.

Having described our invention, we claim:

Claims

1. A stabilized solid pharmaceutical composition comprising a levothyroxine salt and a pharmaceutically acceptable carrier, wherein at least about 85% ofthe levothyroxine dissolves in aqueous solution in less than about 20 minutes as determined by a standard dissolution test.

2. The composition of claim 1, wherein at least about 80% ofthe levothyroxine dissolves in aqueous solution by about 15 minutes as determined by the standard dissolution test.

3. The composition of claims 1, wherein at least about 80% ofthe levothyroxine dissolves in aqueous solution by about 5 minutes as deteπnined by the standard dissolution test.

4. The composition of claims 1 , wherein the composition further comprises microcrystalline β-cellulose.

5. The composition of claim 5, wherein the microcrystalline β-cellulose. has a bulk density of between from about 0.10 g/cm³ to about 0.35 g/cm³.

6. The composition of claim 5, wherein the microcrystalline β-cellulose has a conductivity of less than about 200 μS/cm.

The composition of claim 1, wherein the composition is formulated as a tablet.

8. The composition of claim 8, wherein tablet has a total hardness of between from about

6 to about 14 KP as determined by a standard hardness test.

9.

pharmaceutically acceptable crosscamiellose salt.

10. The composition of claims 1, wherein the In[AUC(0-t)] is between from about 1 to about 5.

11. The composition of claims 2, wherein the In[AUC(0-t)] is between from about 1 to about 5.

T2. AlϊuϊbTiize l phlϊfma ϊe^ sodium, the composition comprising:

a) between from about 1 μg/tablet to about 1000 μg/tablet levothyroxine sodium (USP),

b) between from about 100 mg/ tablet to about 110 mg/ tablet of microcrystalline β- cellulose. NF (Ceolus) having a bulk density of between from about 0.10 g/ cm³ to about 0.35 g/ cm³,

c) between from about 25mg/tablet to about 50mg/tablet of croscarmellose sodium, NF (Ac-di-sol); and

d) between from about 0.5 mg/tablet to about 5mg/tablet of magnesium stearate, NF.

LT

and a pharmaceutically acceptable carrier, wherein the pharmaceutical composition loses less than 0.7% of its activity per month for up to 18 months.

14. The composition of claim 13, wherein the pharmaceutical composition loses less than 0.7% of its activity per month for up to 18 months.

15. The composition of claim 13, wherein the phamiaceutical composition loses less than 0.5% of its activity per month for up to 18 months.

16. The composition of claim 13, wherein the pharmaceutical composition loses less than 0.3%) of its activity per month for up to 18 months.

17. The composition of claim 13, wherein the pharmaceutical composition includes a β-sheet form of microcrystalline cellulose.

18. The pharmaceutical composition of claim 17, wherein at least about 50 weight % ofthe composition weight is β-sheel fonn of microcrystalline cellulose.

19. A stabilized pharmaceutical composition comprising a levothyroxine salt, wherein the composition features a levothyroxine (T4) plasma AUC (0-t) of between from about 450 μg- hour/dl to about 600 μg-hour/dl.

20. The composition of claim 19, wherein the composition features a levothyroxine (T4) AUC (0-t) of between from about 500 μg-hour/dlL to about 550 μg-hour/ dlL.

21. The composition of claims 19, wherein the In[AUC(0-t)] is between from about 1 to about 10.

22. The composition of claims 20, wherein the In[AUC(0-t)] is between from about 1 to about 10.

23; A^"rTon-granulale^^"sugaf-ιree7 arclf-Tree stablliz^^ comprising levothyroxine and a phamiaceutically acceptable earner, in tablet form.

24. The composition of claim 23, wherein the composition further comprises microcrystalline β-cellulose.

25. The composition of claim 24, wherein the microcrystalline β-cellulose. has a bulk density of between from about 0.10 g/cm to about 0.35 g/cm .

26. The composition of claims 24, wherein the microcrystalline β-cellulose. has a bulk density of between from about 0.15 g/cm³ to about 0.25 g/cm³.

27. The composition of claim 24, wherein the microcrystalline β-cellulose. has a conductivity of less than about 200 μS/cm.

28. The composition of claim 24, wherein the microcrystalline β-cellulose. has a conductivity of between from about 0.5 μS/cm. to 50 μS/cm.

29. The composition of claim 23, wherein tablet has a total hardness of between from about 6 to about 14 KP as deteπnined by a standard hardness test.

30. A non-granulated sugar-free, starch-free immediate release pharmaceutical composition comprising levothyroxine and a phamiaceutically acceptable carrier, in tablet form.

31. The composition of claim 30, wherein the composition further comprises microcrystalline β-cellulose.

32. The composition of claim 31 , wherein the microcrystalline β-cellulose has a bulk density of between from about 0.10 g/ cm³ to about 0.35 g/ cm³.

33. The composition of claims 31 , wherein the microcrystalline β-cellulose has a bulk density of between from about 0.15 g/cm to about 0.25 g/cm .

34. The composition of claim 31 , wherein the microcrystalline β-cellulose has a conductivity of less than about 200 μS/cm.

35. The composition of claim 31, wherein the microcrystalline β-cellulose has a conductivity of between from about 0.5 μS/cm to 50 μS/cm.

36. The composition of claim 30, wherein tablet has a total hardness of between from about 6 to about 14 KP as determined by a standard hardness test.

37. A method of administering a levothyroxine pharmaceutical composition to a patient, comprising placing a stabilized levothyroxine pharmaceutical tablet in an aqueous medium, dispersing the levothyroxine composition in the aqueous medium for less than ten minutes, and administering the aqueous medium to the patient.

38. The method of claim 37, wherein the aqueous medium is selected from water, saline, soft drinks and milk.

39. The method of claim 38, wherein the dispersion step is conducted for less than five minutes.

40. A stabilized pharmaceutical composition comprising a levothyroxine salt, wherein the composition features a triiodothyronine (T3) AUC (0-t) of between from about 10 ng-hour/mlL to about 100 ng-hour/mlL

41. The composition of claim 40, wherein the composition features a triiodothyronine (T3) AUC (0-t) of between from about 20 ng-hour/ml to about 60 ng-hour/ml.

42. A stabilized pharmaceutical composition comprising a levothyroxine salt, wherein the composition features a triiodothyronine (T3) AUC (0-t) of between from about 10 ng-hour/mlL to about 100 ng-hour/mlL.

43. The composition of claim 42, wherein the composition features a triiodothyronine (T3) AUC (0-t) of between from about 20 ng-hour/ml to about 60 ng-hour/ ml.

44. The composition of claims 42, wherein the In[AUC(0-t)] is between from about 1 to about 5.

45. The composition of claims 43, wherein the In[AUC(0-t)] is between from about 1 to about 5.

15. A^"slabllϊzed pli fmaceutical

wherein the composition exhibits a levothyroxine (T4) plasma Cmax of between from about 10 μg/dl to about 20 μg/dl as determined by a standard Cmax test.

47. The composition of claim 46, wherein the composition exhibits a levothyroxine (T4) plasma Cmax of between from about 12 μg/dl to about 16 μg/dl as determined by the standard Cmax test.

48. The composition of claims 46, wherein the In(Cmax) ofthe levothyroxine (T4) plasma level is between from about 1 to about 3.

49. The composition of claims 47, wherein the In(Cmax) ofthe levothyroxine (T4) plasma level is between from about 1 to about 3.

507 A^tabllizecl pharmaceuTical compδslfiδTϊ ^mp^s rϊg^le^^ ^alT, wherein he composition exhibits a levothyroxine (T4) plasma Tmax of between from about 0.5 hours to about 5 hours as determined by a standard Tmax test.

51. The composition of claim 50, wherein the composition exhibits a levothyroxine (T4) plasma Tmax of between from about 1 hour to about 3 hours as determined by the standard Tmax test.

52. A stabilized pharmaceutical composition comprising a levothyroxine salt, wherein the composition exhibits a triiodothyronine (T3) plasma Tmax of between from about 10 hours to about 20 hours as detemiined by the standard Tmax test.

53. The composition of claim 52, wherein the composition exhibits a triiodothyronine (T3) plasma Tmax of between from about 12 hours to about 16 hours as determined by the standard Tmax test.

54. An immediate release solid pharmaceutical composition comprising a levothyroxine salt, wherein the composition is essentially sugar free.

55. A stabilized solid pharmaceutical composition comprising a levothyroxine salt, wherein the composition is essentially sugar free.

56. An immediate release solid pharmaceutical composition comprising a levothyroxine salt, wherein the composition is essentially non-granular.

57. A stabilized solid pharmaceutical composition comprising a levothyroxine salt, wherein the composition is essentially non-granular.

58. An immediate release phamiaceutical composition comprising a levothyroxine salt, wherein the composition is formulated as a tablet.

59. The composition of claim 58, wherein the tablet has a total hardness of between from about 1 to about 30 KP as determined by a standard hardness test.

60. The composition of claim 59, wherein tablet has a total hardness of between from about 5 to about 15 KP as detemiined by a standard hardness test.

61. An immediate release solid pharmaceutical composition comprising a levothyroxine salt, wherein the composition is formulated as a tablet.

62. The composition of claim 61 , wherein the tablet has a total hardness of between from about 1 to about 30 KP as determined by a standard hardness test.

63. The composition of claim 62, wherein tablet has a total hardness of between from about 5 to about 15 KP as determined by a standard hardness test.

64. A stabilized solid pharmaceutical composition comprising a levothyroxine salt, wherein the composition is formulated as a tablet.

65. The composition of claim 64, wherein the tablet has a total hardness of between from about 1 to about 30 KP as determined by a standard hardness test.

66. The composition of claim 65, wherein tablet has a total hardness of between from about 5 to about 15 KP as detemiined by a standard hardness test.

67. An immediate release pharmaceutical composition comprising a levothyroxine salt, wherein the tablet is configured to increase heat transfer away from the tablet.

68. The composition of claim 67, wherein the tablet has a surface area of between from about

0.9 in.² to about 0.15 in.².

69. The composition of claims 67, wherein the tablet is beveled.

70. The composition of claims 68, wherein the tablet is beveled.

71. The composition of claim 68, wherein the tablet further comprises a score line.

72. The composition of claim 69, wherein the tablet further comprises a score line.

73. The composition of claim 70, wherein the tablet further comprises a score line.

74. The composition of claims 67, wherein the tablet has a raised violin configuration.

75. The composition of claims 68, wherein the tablet has a raised violin configuration.

76. The composition of claims 69, wherein the tablet has a raised violin configuration.

77. The composition of claims 70, wherein the tablet has a raised violin configuration.

78. The composition of claims 71 , wherein the tablet has a raised violin configuration.

79. The composition of claims 72, wherein the tablet has a raised violin configuration.

80. The composition of claims 73, wherein the tablet has a raised violin configuration.

81: A^~51al5ttιze l^~sOliα^* pharmaceutical composition comp slng a levothyroxine salt, wherein the tablet is configured to increase heat transfer away from the tablet.

82. The composition of claim 81, wherein the tablet has a surface area of between from about 0.9 in.² to about 0.15 in.².

83. The composition of claims 81 , wherein the tablet is beveled.

84. The composition of claims 82, wherein the tablet is beveled.

85. The composition of claim 81 , wherein the tablet further comprises a score line.

86. The composition of claim 82, wherein the tablet further comprises a score line.

87. The composition of claim 83, wherein the tablet further comprises a score line.

88. The composition of claim 84, wherein the tablet further comprises a score line.

89. The composition of claims 81 , wherein the tablet has a raised violin configuration.

90. The composition of claims 82, wherein the tablet has a raised violin configuration.

91. The composition of claims 83, wherein the tablet has a raised violin configuration.

92. The composition of claims 84, wherein the tablet has a raised violin configuration.

93. The composition of claims 85, wherein the tablet has a raised violin configuration.

94. The composition of claims 86, wherein the tablet has a raised violin configuration.

95. The composition of claims 87, wherein the tablet has a raised violin configuration.

96. The composition of claims 88, wherein the tablet has a raised violin configuration.

97. An imnϊediateTelease sδli pliarmaceύϊϊcal composition^" comprising wherein the composition features less than about 10% total impurities as determined by a standard impurity test.

98. The composition of claim 97, wherein the composition features less than about 5% total impurities as determined by the standard impurity test.

99. The composition of claims 97, wherein the impurities comprise at least one of diiodothyronine (T2), triiodothyronine (T3), triiodothyroacetic acid amide, triiodothyroethylamine, triiodothyroacetic acid, triiodothyroethyl alcohol, tetraiodothyroacetic acid amide, tetraiodothyroacetic acid, triiodothyroethane, and tetraiodothyroethane.

100. The composition of claims 98, wherein the impurities comprise at least one of diiodothyronine (T2), triiodothyronine (T3), triiodothyroacetic acid amide, triiodothyroethylamine, triiodothyroacetic acid, triiodothyroethyl alcohol, tetraiodothyroacetic acid amide, tetraiodothyroacetic acid, triiodothyroethane, and tetraiodothyroethane.

101. The composition of claims 97, wherein the impurities detected in the assay consist of diiodothyronine (T2), triiodothyronine (T3), triiodothyroacetic acid, and tetraiodothyroacetic acid.

102. The composition of claims 98, wherein the impurities detected in the assay consist of diiodothyronine (T2), triiodothyronine (T3), triiodothyroacetic acid, and tetraiodothyroacetic acid.

103. Th^~e cδln^όlϊition of claϊn^ of diiodothyronine (T2), triiodothyronine (T3), triiodothyroacetic acid, and tetraiodothyroacetic acid.

104. The composition of claims 100, wherein the impurities detected in the assay consist of diiodothyronine (T2), triiodothyronine (T3), triiodothyroacetic acid, and tetraiodothyroacetic acid.

105 : A^~ΕtHbϊlized ^"solid pharmaceutical composition compπslfigiπevδlhyroxirie ^'salt7/whereϊri the composition features less than about 10% total impurities as determined by a standard impurity test.

106. The composition of claim 105, wherein the composition features less than about 5% total impurities as determined by the standard impurity test.

107. The composition of claims 105, wherein the impurities comprise at least one of diiodothyronine (T2), triiodothyronine (T3), triiodothyroacetic acid amide, triiodothyroethylamine, triiodothyroacetic acid, triiodothyroethyl alcohol, tetraiodothyroacetic acid amide, tetraiodothyroacetic acid, triiodothyroethane, and tetraiodothyroethane.

108. The composition of claims 106, wherein the impurities comprise at least one of diiodothyronine (T2), triiodothyronine (T3), triiodothyroacetic acid amide, triiodothyroethylamine, triiodothyroacetic acid, triiodothyroethyl alcohol, tetraiodothyroacetic acid amide, tetraiodothyroacetic acid, triiodothyroethane, and tetraiodothyroethane.

109. The composition of claims 105, wherein the impurities detected in the assay consist of diiodothyronine (T2), triiodothyronine (T3), triiodothyroacetic acid, and tetraiodothyroacetic acid.

110. The composition of claims 106, wherein the impurities detected in the assay consist of diiodothyronine (T2), triiodothyronine (T3), triiodothyroacetic acid, and tetraiodothyroacetic acid. 1117

diiodothyronine (T2), triiodothyronine (T3), triiodothyroacetic acid, and tetraiodothyroacetic acid.

112. The composition ofclaims 108, wherein the impurities detected in the assay consist of diiodothyronine (T2), triiodothyronine (T3), triiodothyroacetic acid, and tetraiodothyroacetic acid.

113. An immediate release solid phaπnaceutical composition comprising a levothyroxine salt, wherein the composition comprises a phamiaceutically acceptable croscarmellose salt.

114. The composition ofclaims 113, wherein the composition further comprises a pharmaceutically acceptable magnesium salt.

115. A stabilized solid pharmaceutical composition comprising a levothyroxine salt, wherein the composition comprises a pharmaceutically acceptable croscarmellose salt.

116. The composition ofclaims 115, wherein the composition further comprises a pharmaceutically acceptable magnesium salt.

1 17. An immediate release pharmaceutical composition in tablet fomi comprising levothyroxine sodium, the composition comprising:

a) between from about 0.01 mg/tablet to about 500 mg/tablet levothyroxine sodium (USP),

b) between from about 100 mg/ tablet to about 110 mg/tablet of microcrystalline β- cellulose, NF (Ceolus) having a bulk density of between from about 0.10 g/ cm³ to about 0.35 g/ cm³,

c) between from about 25mg/tablet to about 50mg/tablet of croscannellose sodium, NF (Ac-di-sol); and

d) between from about 0.5 mg/tablet to about 5mg/tablet of magnesium stearate, NF.

118. The composition of claim 117, wherein the composition further comprises at least one phamiaceutically acceptable coloring agent.

119. A stabilized pharmaceutical composition in tablet form comprising levothyroxine sodium, the composition comprising:

a) between from about 0.01 mg/tablet to about 500 mg/tablet levothyroxine sodium (USP),

b) between from about 100 mg/tablet to about 110 mg/tablet of microcrystalline β- cellulose, NF (Ceolus) having a bulk density of between from about 0.10 g/ cm³ to about 0.35 g/ cm³,

c) between from about 25mg/tablet to about 50mg/tablet of croscarmellose sodium, NF (Ac-di-sol); and

d) between from about 0.5 mg/tablet to about 5mg/ tablet of magnesium stearate,

NF.

120. The composition of claim 1 19, wherein the composition further comprises at least one pharmaceutically acceptable coloring agent.

121. An immediate release pharmaceutical aqueous liquid comprising a levothyroxine salt.

122. The liquid of claim 121 , wherein the solution is adapted for child or infant use.

123. A method of making an immediate release pharmaceutical composition comprising a levothyroxine salt, the method comprising

a) mixing a levothyroxine salt with microcrystalline β-cellulose and a croscarmellose salt to make a blend; and

b) compressing the blend in a ratio of initial volume to final volume of between from about 2:1 to about 5:1 to make the composition.

124. The method of claim 123, wherein the ratio of initial volume to final volume is about 4:1.

125. The method ofclaims 123, wherein the composition features less than about 5%> total impurities as deteπnined by the standard impurity test.

126. The method ofclaims 124, wherein the composition features less than about 5% total impurities as detemiined by the standard impurity test.

127. The method ofclaims 123, wherein the method further comprises fomiing a tablet.

128. The method ofclaims 124, wherein the method further comprises forming a tablet.

129. The method of claims 125, wherein the method further comprises forming a tablet.

130. The method ofclaims 126, wherein the method further comprises forming a tablet. 131: Ttø nτeth 5dT5røalml23, w l ^

132. The method of claim 124, wherein the tablet has a raised violin configuration.

133. The method of claim 125, wherein the tablet has a raised violin configuration.

134. The method of claim 126, wherein the tablet has a raised violin configuration.

135. The method of claim 127, wherein the tablet has a raised violin configuration.

136. The method of claim 128, wherein the tablet has a raised violin configuration.

137. The method of claim 129, wherein the tablet has a raised violin configuration.

138. The method of claim 130, wherein the tablet has a raised violin configuration.

salt, the method comprising a) mixing a levothyroxine salt with microcrystalline β-cellulose and a crosscamiellose salt to make a blend; and

b) compressing the blend in a ratio of initial volume to final volume of between from about 2:1 to about 5:1 to make the composition.

140. The method of claim 139, wherein the ratio of initial volume to final volume is about 4:

141. The method ofclaims 139, wherein the composition features less than about 5% total impurities as detennined by the standard impurity test.

142. The method ofclaims 140, wherein the composition features less than about 5% total impurities as determined by the standard impurity test.

143. The method ofclaims 139, wherein the method further comprises forming a tablet.

144. The method ofclaims 140, wherein the method further comprises forming a tablet.

145. The method ofclaims 141, wherein the method further comprises fomiing a tablet.

146. The method of claims 142, wherein the method further comprises fomiing a tablet. 147: TheτΗethOdτjT afnτT437 hereirrtteTablet has a raised violin confipfatiom

148. A method of instructing a human to take an immediate release pharmaceutical composition in tablet form comprising levothyroxine, said method comprising:

instructing the human to take a certain number ofthe immediate release phamiaceutical levothyroxine tablets at a selected number of times daily to treat reduced or absent thyroid function.

149. A method according to claim 148, wherein said reduced or absent thyroid function is caused by an etiology selected from the group consisting of myxedema, cretinism and obesity.

150. A method of instracting a human to take a stabilized pharmaceutical composition in tablet form comprising levothyroxine, said method comprising:

instracting the human to take a certain number ofthe immediate release phamiaceutical levothyroxine tablets at a selected number of times daily to treat reduced or absent thyroid function.

151. A method according to claim 150, wherein said reduced or absent thyroid function is caused by an etiology selected from the group consisting of myxedema, cretinism and obesity.